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ABSTRACT 
THE MODULATING EFFECT OF CONJUGATED LINOLEIC ACID (CLA) ON 
CANCER CELL SURVIVAL IN VITRO 
Conjugated linoleic acids (CLA) are geometrical and positional isomers of n-6 
octadecadenoic acid (linoleic acid, LA, 18:2n-6), which form part of a family of essential 
polyunsaturated fatty acids (PUFA). There are 28 identified CLA isomers that mostly found 
in the meat and milk from ruminant animals. CLA has shown to possess a number of health 
benefits including; reduction in body fat and increased lean body mass, prevention of 
atherosclerosis, hypertension, increased immune function and in particular the prevention of 
cancer. The effects of CLA on cancer cell lines will be evaluated to discover the mechanisms 
that are employed to achieve this great phenomenon on cell growth. 
 The aim of this study was to determine the effect of CLA on various parameters that are 
essential in the development of cancer cell phenotype. The objectives were to evaluate the 
effect of CLA on iron-induced lipid peroxidation of microsomes isolated from rat liver cells 
and in vitro cytotoxicity, cell proliferation and apoptosis in HepG2 hepatocarcinoma cells. 
The Fatty acid incorporation in HepG2 cells was also assessed. 
Iron-induced lipid peroxidation was measured by the production of malondialdehyde (MDA) 
as a thiobarbituric acid reactive substance (TBARS), utilising rat liver microsomes. Briefly, 
microsomes were exposed (30 min) to the following FA’s: oleic acid (OA, C18:1n9) and 
vaccenic acid (VA, C18:1n7), linoleic acid: c9t11 CLA, t10c12 CLA, α-linolenic acid (ALA, 
C18:3n3), and γ-linolenic acid (GLA, C18:3n6) before lipid peroxidation was measured. 
Cytotoxicity, cell viability, apoptosis and cell proliferation in HepG2 cells was measured 
after 48 hour treatment to determine the effect of the CLA isomers, LA and α-linolenic acid 
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(ALA) on these parameters. For FA incorporation, cells were supplemented with 
concentration of FA-BSA complexes for 48 hours. FA were extracted, separated into 
respective phospholipid fractions (PC and PE) and measured by gas chromatography. 
Cholesterol and phospholipid concentrations were also quantified by cholesterol enzymes and 
malachite green methods respectively. 
The t10c12 CLA isomer tended to exhibit weaker protection against lipid peroxidation than 
the c9t11 isomer although the difference was not statistically significant. The c9t11 CLA 
isomer exhibited greater cytotoxicity and increased apoptosis compared to t10c12 CLA 
(P<0.05). Both CLA isomers significantly reduced cell proliferation (P<0.05). CLA did not 
significant affect cholesterol and phospholipid concentration. The c9t11 CLA isomer 
increased the concentration of all fatty acids in both the PC and PE phospholipid fractions. 
The t10c12 CLA isomer significantly reduced the MUFA concentration in both PC and PE 
fractions. 
The c9t11 CLA isomer markedly increased apoptosis and the overall FA content. MUFA 
concentrations increased, reducing susceptibility to lipid peroxidation, thereby preventing 
cellular stress. c9t11 Increased total FA content of the cell membrane, suggesting increase de 
novo synthesis of FA required for the formation of new cells. However, it could also be 
implicated in the formation of apoptotic bodies, which are membranous bodies containing 
cell fragments that are formed at the end of the apoptosis process. The t10c12 CLA isomer 
reduced the activity of delta-9 desaturase due to decline in MUFA composition of the cell 
membrane. Reduced delta-9 desaturase activity limits FA availability for proliferation of new 
cells. The anti-cancer mechanisms that are in place await full explanation, therefore further 
studies in cycle events and gene expression are required to fully uncover the anticancer effect 
of both c9t11 and t10c12 CLA isomers.      
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1.1. Introduction 
Since its discovery, conjugated linoleic acid (CLA) has received a great deal of interest in 
scientific research as well as the public eye. Limited recent information is available that 
addresses the cellular effect of CLA n cancer cells. The anticarcinogenic potential of CLA 
was found by chance when beef hamburger patties reduced tumour growth by more than 50% 
(Pariza et al., 1979). This sparked the interest in identifying and studying the active element 
of these beef patties that was responsible for inhibiting tumour cell growth. Later findings 
showed that the element was in fact a conjugated derivative of linoleic acid (LA) (Nunes et 
al., 2008). CLA has since been shown to possess activity against the development of many 
diseases such as atherogenesis, obesity and, for the purpose of this study, most importantly 
carcinogenesis (Nagao and Yanagita, 2005).  
Cancer has for many years been an imperative research focus area. This is due to its ability to 
develop at any point in the life of an individual. Cancer is described as the uncontrolled 
growth of cells (WHO, 2009). However, it is now known that many underlying factors exist 
in the development of tumourigenic cells. These factors have been designated “The 
Hallmarks of Cancer” (Hanahan and Weinberg, 2011). These characteristics are essential for 
the development of tumorous cells and are discussed in chapter 2, with emphasis placed on 
those important in this study. Cancer prevention and therapeutic endeavours have been set out 
to target at least two cancer hallmarks to be an effective agent. The activity of CLA against 
the growth of cancer cells has shown to involve apoptosis, cell proliferation, immune 
response modulation as well as cell cycle events (Crumb, 2011). These studies employed a 
combination of the two main CLA isomers found, cis9-trans11 (c9t11) CLA and trans10-
cis12 (t10c12) CLA. However, the isomers of CLA could possess different mechanisms that 
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are yet to be defined (Rossi et al., 2012). Therefore CLA remains an effectual treatment 
possibility due to its easy introduction into the diet of an individual. 
The current project evaluated the respective oxidant potential of two CLA isomers, c9t11 
CLA and t10c12 CLA, in a rat liver microsome modal as well as the modulating effect on 
HepG2 human hepatocarcinoma cell survival and fatty acid incorporation. These two isomers 
are found in the greatest proportion of total CLA in meat and milk of ruminant animals. 
Chapter 2 provides a vital review of literature on cancer, chemotherapy, cell membrane 
components and important processes involved in tumourigenesis. Also discussed is the 
history of CLA and current knowledge on its anticarcinogenic properties. Chapter 3 looks at 
the antioxidant potential of two CLA isomers and compares it to five 18-carbon fatty acids 
(C18 FA) belonging to monounsaturated and polyunsaturated fatty acid families. 
Polyunsaturated fatty acids are susceptible to lipid peroxidation, which induces oxidative 
stress. Cancer cells have high antioxidative nature, therefore increased intracellular oxidative 
stress can induce apoptosis, a possible anti-tumour mechanism (Verrax et al., 2009). The 
cytotoxic effect of the two CLA isomers and their effect on apoptosis and cell proliferation 
are discussed in detail in chapter 4. Chapter 5 presents data regarding the fatty acid 
incorporation of the two CLA isomers and the modulating effects in the cell membrane fatty 
acids composition in HepG2 cells. The main findings of the study will be integrated and 
summarized in Chapter 6, while supportive experimental procedures will be summarized in 
the Addendum section. 
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Literature review 
2.1. Introduction 
It is becoming well recognized that, at least in the long term, future advances in clinical 
cancer research will come from an emphasis on prevention rather than the treatment of 
metastatic disease. This endeavor aims to develop compounds that are especially effective 
against the development and progression of cancer cells and are not harmful or toxic to 
normal healthy cells. Cancer cells exhibit several hallmarks such as: extensive cell 
proliferation, hyperactive metabolism, genomic instability and evasion of apoptosis (Table 
2.1) (Negrini et al., 2010). These hallmarks provide a dense foundation for cancer research, 
and have served to identify therapeutic targets within a cell (Hanahan and Weinberg, 2000).  
 
2.2. Cancer and chemoprevention 
Cancer, tumors or neoplasm’s refer to a broad group of diseases, which can affect anyone at 
any stage in their lives. A tumour begins with genomic instability and uncontrollable, 
unregulated growth of abnormal cells that may spread and affect other organs. Tumour cells 
that have spread are metastatic and the leading cause of death worldwide with 7.6 million 
deaths (around 13% of all deaths from all diseases) in 2008 (Jemal et al., 2011). It is 
estimated that in 2030 cancer would claim approximately 12 million lives globally (WHO, 
2009). Of this number only about 5–10% of all cancer cases have been accredited to 
hereditary genetic imperfections. The remaining 90–95% of cancer cases was influenced by 
external risk factors within the environment. These risk factors include; cigarette smoking, 
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diet, alcohol, sun exposure, environmental pollutants, infections, stress, obesity, and physical 
inactivity (Anand et al., 2008).  
Cancer incidence rises with age, which is an essential factor in tumor development. As the 
body ages, mechanisms whereby the body repair itself do not operate as efficiently, therefore 
when a cell is under stress, the DNA repair machinery does not function properly. This will 
result in mutations in the DNA and the development of a tumor (Gorbunova V. et al., 2007). 
The type of cancer can be classified by stage, pathology, grade, receptor status, and the 
presence or absence of genes as determined by DNA testing (Romond E.H., 2005, Sotirou C. 
and L., 2009). A great deal of research has gone into the development of chemoprevention 
agents that would actively target and interrupt tumour development in vivo; however clinical 
testing is unethical without sufficient in vitro evidence of cellular effects of the compounds.  
Cancer is a disease involving dynamic changes in the genomes that result in the abnormal 
growth of a cancerous lesion. The etiology of cancer encompasses a series of events that may 
require up to 20 years developing. No less than three gene classes are involved in tumour 
initiation: these are oncogenes, tumour suppressor genes, and DNA repair genes (Tysnes and 
Bjerkvig, 2007). During the first stage an oncogene develops within the DNA of somatic cells 
(Figure 2.1). Oncogenes are mutated genes that are responsible for normal growth of cells 
(Croce, 2008). The mutated DNA are either not repaired or repaired incorrectly through DNA 
repair enzymes ultimately leading to atypical proliferation of single cells. Tumour suppressor 
genes are altered and cannot perform its natural function thus producing excessive cell 
proliferation that is uncontrolled, leading to the outgrowth of a population tumor cells, 
establishing a primary tumour site (Fearon and Bommer, 2008). Mutations may occur mainly 
when an individuals’ genetic factors interact with various external agents such as; ultraviolet 
and ionizing radiation, asbestos, components of tobacco smoke, aflatoxin (a food 
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contaminant) and arsenic (a drinking water contaminant), infections from certain viruses, 
bacteria or parasites (WHO, 2009). Chemoprevention, targeting cancer induction, aims to 
inhibit cell proliferation and stimulate repair of cell machinery to ensure the progression of 
normal growth phases. During the promotion stage of cancer development, through clonal 
expansion, cells proliferate excessively without dying forming a tumour growth (Tysnes and 
Bjerkvig, 2007). After establishment of the primary tumour, cells invade and penetrate the 
blood vessels and enter the circulatory system. The tumour becomes metastatic and results in 
a secondary tumor at a distant location in the body. This is the progression and  final stage of 
cancer development (Martini F.H. and Ober, 2005).  
 
Figure 2.1: The Process of Carcinogenesis and possible targets for Chemoprevention 
(DKFZ, 2013). The three stages of carcinogenesis: Initiation, promotion and progression may 
take between 10 and 20 years to fully develop. 
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Cell biology is a branch of science that deals with understanding and explaining in vivo 
cellular activities by conducting in vitro experiments. The main target for chemotherapy 
drugs is the induction of apoptosis and the prevention of cellular repair mechanisms. Because 
of the highly adaptability of cancer cells and development of drug resistant tumours, it has 
been suggested that targeting at least two hallmark pathways simultaneous may lead to more 
effective cancer therapies (Hanahan and Weinberg, 2000). 
 
2.2.1. Hallmarks of cancer  
 A review by Hanahan and Weinberg, 2011 identified six acquired capabilities of cancer 
cells.  These “hallmarks of cancer” (Hanahan and Weinberg, 2000), has provided the basis 
for approaching new therapies. The authors have since expanded the  list to ten features 
(summarized in Table 2.1) of cancer cells that are essential for developing their distinctive 
phenotype (Hanahan and Weinberg, 2011).  
 
2.2.1.1. Activated growth signals  
This is arguably the most essential trait of cancer cells involving their ability to sustain 
chronic proliferation signals. Production and release of growth-promoting signals are highly 
controlled in normal cells to ensure homeostasis is preserved and thus upkeep of normal 
tissue architecture and function. These pathways maintain a balance between cell death and 
cell survival signals (Tzur et al., 2009). 
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Table 2.1: The Hallmarks of cancer 
 Hallmarks Description 
1. Activated growth signals Most fundamental trait of cancer cells can 
be achieved through various mechanisms. 
2. Unresponsive to anti-growth    signals Evasion of both intracellular and 
extracellular growth suppressor signals. 
3. Evading apoptosis Resisting cell death signals. 
4. Infinite reproductive ability Reproductive immortality induced by 
avoiding apoptotic and senescence triggers 
5. Prolonged angiogenesis Sustain expanding neoplastic growths. 
6. Tissue invasion and metastasis Tumour cells ‘break off ‘from the original 
tumour site, enter the blood steam and 
invade distal tissues. 
7. Genomic instability Generation of random mutations including 
chromosomal rearrangement. 
8. Inflammation  Tumour promoting inflammation that helps 
to acquire hallmark capabilities. 
9. Reprogramming energy metabolism Fuel cell growth and division. 
10. Evading immune destruction Longstanding tumours avoid detection by 
the immune system or have limit the extent 
of immunological killing. 
(Hanahan and Weinberg, 2000, Hanahan and Weinberg, 2011)  
Cancer cells receive growth signals through numerous mechanisms. They produce growth 
factor ligands, which result in autocrine proliferative stimulation and stimulate surrounding 
cells to produce various growth factors to sustain the cancer cells. Deregulation of receptor 
signaling in tumour cells can also occur by increasing the levels of receptor proteins, 
rendering a hyper-responsive state to a relatively low amount of growth factor ligand. These 
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adaptations by tumour cells contribute to the development and maintenance of tumour 
morphology. 
 
2.2.1.2. Unresponsive to anti-growth signals  
Two major tumor suppressors key in cell growth control encode the retinoblastoma (Rb) and 
p53 proteins (Szekely et al., 1993).  
The Rb pathway acts as a crucial gatekeeper of cell-cycle progression and any defects or 
absence permits continual cell proliferation. P53 integrates stress and abnormality sensors 
within the cell’s intracellular operating systems. Excessive DNA damage or suboptimal levels 
of nucleotides, growth promoting signals, glucose or oxygen increase p53 levels that lead to 
inhibition of cell-cycle progression allowing for either DNA excision repair or induction of 
apoptosis (Hanahan and Weinberg, 2011).  
 
2.2.1.3. Evading apoptosis  
Apoptosis is a form of programmed cell death that requires energy to activate biochemical 
pathways that kill the cell in a neat and orderly manner. (Vaculova A. et al., 2010, O’Brien 
M.A. and Kirby R., 2008, Sreedhar A. S. and P., 2004).  
Evading apoptosis is a key role likened to cancer cell morphology. There are three known 
pathways leading to apoptosis, as outlined in Figure 2.2. The extrinsic pathway is stimulated 
via death receptors on the cell membrane. The intrinsic pathway is stimulated by homeostatic 
changes that result in mitochondrial damage. The third pathway involves immune cytotoxic T 
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cells, which stimulate perforin incorporation in the cell membrane and release granzyme A 
and B intracellularly. Activation of caspase 3 via any of the mentioned pathways leads to 
activation of execution caspases resulting in the formation of apoptotic bodies and the final 
stage of apoptosis (Elmore, 2007). Apoptosis, like many other biological processes, can be 
disrupted by mutation in cancer cells (Lowe and Lin, 2000). With the loss of this function, 
cells containing mutated DNA have no cell death trigger, which result in the multiplication of 
functionally abnormal cells. 
 
 
Figure 2.2: Apoptotic pathways (Elmore, 2007). Diagram displaying the different 
pathways leading to programmed cell death. Three distinct pathways namely; extrinsic 
pathway (death signal is received from outside the cell), intrinsic pathway (death response to 
intracellular stress signals) and finally granzyme pathway (involving granzyme complexes). 
All three pathways lead to apoptosis via caspase 3. 
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2.2.1.4. Enabling and emerging hallmarks 
The above hallmarks of cancer are acquired functional capabilities that allow cancer cell to 
survive, multiply and spread. Genomic instability in cancer cells creates random mutations 
that enable the tumorigenic process. while the inflammatory state of premalignant lesions 
also contribute to tumor progression (Hanahan and Weinberg, 2011). 
Furthermore major reprogramming of cellular energy metabolism is effected by cancer cells 
to maintain their growth, proliferation and metabolic program (Negrini et al., 2010)   and  
evasion of immune destruction by cancer cells enhances tumor development and progression 
(Kim R, 2007). These hallmarks facilitate the development and progression of many forms of 
human cancer and can be measured as emerging hallmarks of cancer.  
 
2.3. Cell membrane 
A biological membrane present in all cells that protects its interior from the external 
environment. The cell membrane regulates substances entering and leaving cells through its 
selectively permeability to ions and organic molecules. The structure of the cell membrane is 
a phospholipid bilayer embedded with proteins (Figure 2.3). Cell membranes are involved in 
a number of cellular processes including cell adhesion, ion conductivity and cell signaling 
and serve as the attachment surface for several structures like the cell wall, glycocalyx, and 
intracellular cytoskeleton (Edidin, 2003).  
The cell membrane structure is composed of a combination of three classes of lipids with 
amphipathic properties: phospholipids, glycolipids, and sterols. The individual quantity of 
each depends upon the cell type, but in most cases phospholipids are most abundant (Alberts 
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et al., 2002). Lipids are important biological molecules, which include fats, sterols, 
glycerides, fat- soluble vitamins and phospholipids that functions as energy stores, signaling 
molecules, and structural components of cellular membranes. These molecules have low 
water solubility, but are highly soluble in nonpolar solvents, making them hydrophobic 
(containing nonpolar groups) or amphipathic (both polar and nonpolar groups), possessing 
properties that are both hydrophilic and lipophilic. (van Meer et al., 2008).  
Lipids are vital components of eukaryotic cells. They are responsible for numerous functions 
in the cell namely; energy storage, cellular matrix formation,  protein aggregation and 
dispersion within the cell membrane and finally act as first and secondary messengers in 
signal transduction and molecular recognitions processes (van Meer et al., 2008). 
Phospholipids, one of the different classes of lipids, are a major element in the lipid bilayer of 
cellular membranes. Most phospholipids contain a diglyceride, a phosphate group, and a 
simple organic molecule such as choline. Glycerophospholipids, a glycerol-based 
phospholipid, are the main type of phospholipids in the biological membranes and include: 
phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylserine (PS), 
phosphatidylinositol (PI) and phosphatidic acid (PA) (Zhang and Rock, 2008). 
 
2.3.1. Phospholipids 
Phospholipids are a class of lipids that are a major component of all cell membranes as they 
can form lipid bilayers. Most phospholipids contain a phosphate group, a simple organic 
molecule such as choline or ethanolamine and two fatty acid (FA) chains. The nonpolar 
Carbon-Hydrogen bonds found in the hydrocarbon chains are incapable of water interaction, 
making them hydrophobic in nature. This, together with the naturally hydrophilic nature of 
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carboxyl groups, gives FAs their amphiphatic properties, which describes the behaviour of 
phospholipids in biological membranes (van Meer et al., 2008).  
 
 
Figure 2.3 Cell membrane lipid bilayer (Muskopf, 2010). Diagram show the mammalian 
cell membrane containing 2 lipid layers embedded with proteins. 
 
2.3.1.1. FA chains 
The FA chains in phospholipids and glycolipids usually contain an even number of carbon 
atoms (14 to 24), with the exception of a few marine organisms with odd numbers of carbon 
atoms. They are found in two forms, saturated and unsaturated (Figure 2.4). Saturated FA 
(SATS) contain no double bonds and therefore all carbons are saturated by single hydrogen 
bonds. They are extremely flexible and found in diverse conformations. Because SATS can 
pack closely together, they can form inflexible arrangements under certain conditions, 
thereby reducing fluidity of mosaic cellular membranes. Unsaturated FAs are slightly more 
abundant in nature than SATS. An unsaturated FA has one or more C-C double bonds in its 
 
 
 
 
17 
 
hydrocarbon. When only one double bond is found, the FA is called monounsaturated fatty 
acids (MUFA), when two or more double bonds are present, the FAs are called 
polyunsaturated fatty acids (PUFA). Unsaturated FA are found in either cis or trans 
configuration, which create a kink, preventing the FAs from packing together as tightly, thus 
decreasing the melting temperature and increasing the membrane fluidity. Unsaturated FA are 
also distinguished according to the position of the first double bond from the methyl end of 
the hydrocarbon chain. As in in Figure 2.4, oleic acid has 18 carbons in the fatty acid chain 
and 1 double bond at position 9 from the methyl end hence 18:1n9. Whereas, linoleic acid has 
18 carbon, 2 double bond, with the first from the methyl end at position 6, hence 18:2n6. 
 
Figure 2.4: Three 18 carbon (C18) FAs (Tvrzicka et al., 2011). Saturated FA, steric acid, 
MUFA, oleic acid, and PUFA, LA (LA). 
 
In its entirety, the cell membrane is supported via non-covalent interaction of hydrophobic 
tails. Under physiological conditions phospholipid molecules in the cell membrane are in a 
distinct phase of matter between solid and liquid states called the liquid crystalline state. This 
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means that the lipid molecules are able to diffuse laterally along their present layer. However, 
the exchange of phospholipid molecules between intracellular and extracellular leaflets of the 
bilayer is a very slow process (Muskopf, 2010).  
 
2.3.2. Cholesterol 
In animal cells cholesterol is normally found dispersed in varying degrees throughout cell 
membranes, in the irregular spaces between the hydrophobic tails of the membrane lipids, 
where it confers stiffening and strengthening effects on the membrane. Lipid rafts are 
examples of cholesterol-enriched micro domains within the cell membrane. Through 
interaction with non-polar FA chains of the cell membrane, cholesterol increase membrane 
packing and decrease membrane fluidity (Scirica and Cannon, 2005). 
 
2.4.1. FA metabolism  
Essential fatty acids (EFA) are FAs required from the diet because of the inability of humans 
to synthesize these FA. These include two main EFA; linoleic acid (LA, C18:2n6) and α-
linolenic acid (ALA, C18:3n3). Once in the human system, these C18 FA can be elongated 
by elongase enzymes and desaturated by desaturase enzymes to produce more biologically 
active FAs like; γ-linolenic acid (GLA, C18:3n6), arachidonic acid (AA, C20:4n6), 
docosahexaenoic acid (DHA, C22:6n3) and eicosapentaenoic acid (EPA, C20:5n3) (Tvrzicka 
et al., 2011) as outlined in Figure 2.5.  
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Omega-3 (N3) FAs have its first double bond at carbon position 3 from the methyl end of the 
FA chain, whereas omega-6 (N6) FA is at position 6. Omega-3 (N3) and omega-6 (N6) EFAs 
are best characterized by their interactions. Arachidonic acid (AA) is a 20-carbon n6 EFA 
that is the major compound of the AA cascade, involving more than 20 different signalling 
paths that regulator a number of different biological functions, including functions involving 
inflammation. LA (LA), an EFA, is acquired from vegetable oils and animal fats, and is the 
precursor for the majority of AA in the body (Burr et al., 1930).  
EPA has been associated with anti-inflammatory effects. It is on the same level of the FA 
metabolic pathway as AA (Figure 2.4) and they compete for Δ5-desaturase enzyme upstream, 
but their downstream products also compete. The enzymes in the FA pathway a greater 
affinity for N3  FA and therefore, a deficiency in N3 FA have been associated with 
inflammatory related diseases for example, arthritis, atherosclerosis and cancer (Riediger et 
al., 2009, Williams et al., 2011). 
 
2.4.2. Role of PUFA in disease and cancer 
An extensive body of research discusses the role of PUFA in health and disease (Simopoulos, 
1991, Calder, 1997, Calder, 2006). The omega 6/3 (N6/N3) ratio was found to be a major 
concern to the health of modern man (Simopoulos, 1991). The ratio increased from about 1 to 
between 10:1 and 25:1, indicating a clear deficiency in N3 FAs in the modern Western diet. 
 
 
 
 
 
 
20 
 
2.4.2.1. FAs as precursors of lipid mediators 
FAs of the cell membrane are precursors of lipid mediators, with eicosanoids (prostaglandins, 
PG; thromboxanes, TX; leukotrienes, LT) being one of the most important. Eicosanoids 
contain 20 carbon atoms, specifically PUFA derived from the sn-2 glycerol carbon (hydroxyl 
group on the second carbon in the FA chain) of cell membrane phospholipids, such as AA 
and EPA. Other FA such as DHA, docosapentaenoic acid (DPA; 22:5n-3) and LA are also 
precursors of various other lipid mediators (Kremmyda et al., 2011, Calviello et al., 2006).  
 
 
Figure 2.5: Dietary essential FA pathways (Nakamura and Nara, 2003). Linoleic acid 
(LA), γ-linolenic acid (GLA), dihomo-γ-linolenic acid (DGLA), arachidonic acid (AA), α-
linolenic acid (ALA), eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA). 
 
 
 
 
 
21 
 
Phospholipases assist the release of cell membrane FAs, which are transformed by 
cyclooxygenase (COX) type 1 and 2 to PG and TX (Berquin et al., 2011). These eicosanoids 
are basic hormones or regulating molecules that appear in most organisms. Unlike endocrine 
hormones, which travel in the blood stream, eicosanoids have autocrine or paracrine actions. 
They alter the activity of the cells from which they were synthesized and of adjoining cells. 
PGs stimulate inflammation, regulate blood flow to particular organs, control ion transport 
across membranes, and modulate synaptic transmission. TXs are vasoconstrictors and potent 
hypertensive agents which also facilitate platelet aggregation (Kremmyda et al., 2011).  
The effect of lipid mediators produced is dependent on their FA substrate. Different 
eicosanoids are produced from AA and EPA, which have different actions. For example, AA 
is the precursor of 2-series PG and 4-series LT, and EPA is the precursor of 3-series PG and 
5-series LT. The AA-derived PG and LT are synthesized in response to injury or cellular 
stress, whereas the EPA-derived PG and LT appear to control the effects of 2-series PG and 
4-series LT produced from AA. EPA-derived PG are formed at a slower rate and weakens the 
effects AA-derived PG. Sufficient production of these PG appears to defend against heart 
attack and stroke as well as certain inflammatory diseases such as arthritis, lupus, and asthma 
(Calder, 2003).  
 
2.4.2.2. FAs in signal transduction 
Signal transduction is the process of activation of a cell surface receptor through extracellular 
signal molecules, creating an intracellular response. The process occurs in two stages. Firstly, 
a signaling molecule activates a specific receptor on the surface membrane of the cell. Then a 
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second messenger transmits the signal intracellularly that produces a physiological response 
(Lodish et al., 2000). 
Cell membrane FAs have been identified to play the role of second messenger and 
modulators of signal transduction. This regulation may be positive or negative, all part of a 
feedback control mechanism, since phospholipases are also controlled by FA (Sumida et al., 
1993). FA act as second messengers in the inositide phospholipid and the cyclic AMP signal 
transduction pathways. They are also modulators that may intensify, weaken or diverge a 
signal. FAs modify the activities of many stimulus-response coupling mechanisms such as 
phospholipases, protein kinases (PKC), G-proteins, adenylate and guanylate cyclases as well 
as ion channels and other biochemical events involved (Graber et al., 1994). The activation of 
PKC is dependent on the lipid and FA composition of membrane phospholipids (Nishizuka, 
1992). 
 
2.4.2.3. Oxidative stress 
Oxidative stress is defined as a disruption in the equilibrium between the reactive oxygen 
species (ROS) and antioxidant production in cells. The excessive ROS leads to free radical 
damage and the induction of lipid peroxidation (Betteridge, 2000). Persistent exposer to 
oxidative stress has been associated to numerous biological disorders such as cancer. The 
active role of oxidative stress in cancer has been correlated to activated transcription factors 
and proto-oncogenes, genomic instability, chemotherapy-resistance, invasion and metastasis 
(Toyokuni et al., 1995).  
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Figure 2.6: Lipid peroxidation of unsaturated FAs (Vickers, 2007). Diagram showing the 
process of lipid peroxidation on unsaturated FA forming lipid peroxides.  
 
Unsaturated FAs are highly susceptible to lipid peroxidation. Some studies show that FA can 
activate oxidative stress and production of prothrombotic markers (Soardo et al., 2011). One 
study even shows that a saturated FAs enriched diet offers protection against oxidative stress 
(Lemieux et al., 2011). As outlined in Figure 2.6, exposure of unsaturated FAs to free radicals 
(-OH) initiates the process of lipid peroxidation and formation of lipid radicals. The lipid 
radicals are propagated by oxygen (O2) to form lipid proxyl radicals and ultimately lipid 
peroxides. Accumulation of lipid peroxides has been implemented in certain diseases and 
cancer (Yagi, 1987). Cancer cells show a loss in lipid peroxidation early in the tumorigenic 
process that has been attributed to change in lipid profile of cellular membranes, with a clear 
decrease in polyunsaturated FAs, the key substrate for lipid peroxidation (Dianzani, 1989). 
Some studies suggest increasing PUFA content of the cell membrane would increase lipid 
peroxidation and increase the oxidative stress in cancer cells (Barrera, 2012). 
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2.5. Conjugated Linoleic Acid 
Conjugated linoleic acids (CLA) refer to a group of FAs which are geometrical, cis or trans, 
and positional, position of double bond, isomers of octadecadenoic acid (LA) (Aydin, 2005). 
An increasing interest in CLA is attributed to its potential health benefits such as 
anticarcinogenic, antiatherogenic, antidiabetic and antiadipogenic effects. In the FA chain of 
CLA there are two conjugated double bonds at different carbon positions. They form part of 
the omega 6 family of essential PUFAs containing 2 double bonds in its chemical structure 
(Christie et al., 2007). There are 28 CLA identified isomers, which produced naturally in the 
rumen and milk udders of ruminant animals (grazing cows). The two major and most 
extensively studied isomers are cis9-trans11 CLA (c9t11 CLA), also called rumenic acid) 
and trans10-cis12 CLA (t10c12 CLA). The c9t11 CLA isomer is the most prevalent CLA 
isomer present in milk fat and beef (about 70-90 % of total CLA content), whereas the 
concentration of the t10c12 CLA isomer (3-5 %) vary considerably depending of 
consumption, grazing or feed fed, of these animals (Collomb et al., 2004, Park et al., 2001, 
Khanal and Dhiman, 2004).  Total conjugated dienes (CD) content of milk fat and meat are 
also season dependent. During spring and summer, grazing months, CD content is higher than 
during autumn and winter, feed fed months.  
Numerous studies exemplify health benefits of CLA in mouse system, such as anticancer, 
adipogenic, antiatherogenic and increase immune function (Smedman and Vessby, 2001, 
Aydin, 2005). These benefits raise interest in studying and understanding mechanisms that 
CLA would protect humans from these disorders. Each isomer however shows different 
biological activity. For example, c9t11 CLA isomer has shown to reduce the risk cancer 
development in mouse (van Meer et al., 2008), whereas t10c12 CLA isomer plays a more 
active role in reducing body fat (Muskopf, 2010). It is therefore important to study each 
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isomer individually and also various combinations to fully understand how they react in the 
body. 
 
2.5.1. History of CLA 
The first reported incidence of the presence of conjugated FA in milk fat was by Booth et al. 
(1935) by demonstrating the occurrences of seasonal differences in FA composition of milk 
fat. While doing spectrophotometric analyses of milk fat, they observed marked increase in 
absorption at 230 nm when comparing winter to summer milk fat, when cows were changed 
on to pasture feed (Booth et al.). This increase absorption at 230 nm was later accredited to 
the presence of conjugated double bonds by Moore (1939) (Khanal and Dhiman). Hilditch 
and Jasperson suggested C18 PUFA chains displayed conjugated unsaturation (Ha et al., 
1990, Kemp and Lander, 1984, Palmquist et al., 2005). Shorland et al (1957) supported this 
by showing that PUFAs are hydrogenated, biohydrogenation, in the rumen of cows (Bauman 
et al., 2000). Bartlett and Chapman proposed conjugated intermediate in reactions leading to 
the conversion of LA to trans11-vaccenic acid in the rumen. This was after the discovering a 
constant relationship between trans-C18:1 and conjugated unsaturation determined by 
differential infrared spectroscopy (Floor et al., 2012). A few years later while studying milk 
fat FA profiles of 29 creameries across Canada for every month of the year, Riel (1963) 
found that cows grazing on pasture during summer months yielded twice the amount of 
conjugated dienes in milk fats as when cows were fed total mixed rations (TMR) during 
winter (Søreide et al., 2009). These findings confirmed Booths’ observations in 1935.  
Kepler et al. (1966) investigated the process of biohydrogenation by rumen bacteria 
Butyrivibrio fibrisolvens in the reduction of LA to stearic acid. They confirmed B. 
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fibrisolvens specificity for LA and proposed an intermediate step in the reduction process. In 
the first step of biohydrogenation, LA isomerization occurred forming a conjugated cis-trans 
octadecadienoic intermediate, which is subsequently hydrogenated and trans-monoenoic 
acids are formed (Milinkovic et al., 2012). Kepler and Tove (1967) later confirmed the cis-
trans octadecadienoic intermediate formed following isomerization of LA to be cis9-trans11 
octadecanoic acid, which was the first time c9t11 octadecanoic acid was identified in the 
rumen (Beckman, 2009). Later, Parodi (1977) was first to establish the presence of c9t11 
octadecanoic acid in milk fat by isolating conjugated cis, trans- octadecadienoic acids and 
studying their FA profiles through gas liquid chromatography (Bissonauth et al., 2006). In 
1987, Ha et al. inhibited mutagenesis in bacteria and reduced chemically induced epidermal 
carcinogenesis in mince using fried ground beef. They said that the responsible compound is 
an isomeric derivative of LA containing a conjugated double-bond, and called it CLA (CLA) 
(Nunes et al., 2008). They then induced epidermal cancer in mice and treated them with LA 
and CLA. When compared to LA, CLA treated mice produced half as many papillomas and 
exhibited a lower tumor incidence.   (Fa et al., 2005). For the first time, CLA was shown to 
have a potential benefit in reducing cancer development. 
 
2.5.2. Structure of CLA 
The term CLA has been dedicated to a number of positional and geometrical isomers of an 
essential PUFA, LA. PUFA, together with saturated and MUFA, are integral constituents of 
triglycerides, phospholipids and other complex lipid molecules, and therefore form an 
essential part of cell membranes (Iannone et al., 2009). PUFAs have a common structure of a 
hydrocarbon chain containing two or more carbon-carbon double bonds. Figure 2.7 illustrates 
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structural differences of the two most extensively studied CLA isomers compared to its 
parent FA, LA. Like LA, CLA has two carbon double bonds, but these two double bonds are 
separated by a single hydrogen bond found in either ‘cis’ or ‘trans’ configuration and are 
therefore termed ‘conjugated’ (Nunes et al., 2008). Compared to other dienes, the double 
bonds are either separated by a methylene group or two single hydrogen bonds. The CLA 
double bonds of may occur in the 7,9; 8,10; 9,11; 10,12; or 11,13 positions (Reynolds and 
Roche, 2010) and geometrically in cis-cis, cis-trans, trans-cis or trans-trans configuration. 
There are 28 identified structurally different isomers of CLA found in various concentrations 
in beef and dairy products of ruminants (Banni, 2002). The c9t11 CLA isomer accounts for 
about 80-90% of total CLA content (Cho et al., 2006), t10c12 CLA and other CLA isomers 
are found in very small amounts (Brown et al., 2001). In addition to structural differences 
between CLA isomers, they also show to differ functionally (Tricon et al., 2004). 
 
Figure 2.7: Structure of c9t11 CLA isomer, t10c12 CLA isomer and LA (Mooney et al., 
2012). Diagram comparing the structure of c9t11 CLA and t10c12 CLA to LA. The double 
bonds of the conjugated FAs was separated by one single bond, whereas the double bonds of 
LA are separated by 2 single bonds. 
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2.5.3. Biosynthesis of CLA 
CLA was first discovered to be present in milk fat and meat of ruminant animals. It was later 
found to be produced in the rumen as a conjugated intermediate in the process of 
biohydrogenation of dietary FAs by ruminal bacteria (Kemp and Lander, 1984). Although the 
yield of CLA was significant, this only accounted for a fraction (10-15%) of CLA present in 
the meat and milk of these animals (Bauman et al., 2003). Therefore another process had to 
be involved in the endogenous formation of CLA (Khanal and Dhiman, 2004). CLA was 
subsequently found to be produced through endogenous conversion of transvaccenic acid 
(TVA), a later intermediate during biohydrogenation, to CLA in tissues. The formation of 
CLA is now accepted to have two biosynthetic origins, the rumen and endogenously in 
tissues, occurring in ruminants as well as to lesser extent non-ruminants (Khanal and 
Dhiman, 2004). 
 
2.5.3.1. Ruminal synthesis of CLA 
Two CLA isomers, c9t11 and t10c12 CLA, have previously been shown to be synthesized in 
the rumen of ruminant animals through a process called biohydrogenation (Crumb, 2011). 
Biohydrogenation requires free FAs for initiation and is the second foremost conversion of 
dietary lipids in the rumen following lipid hydrolysis (Palmquist et al., 2005). Pure cultures 
of ruminal organisms were used to establish biohydrogenation pathways. Two groups of 
bacteria, classified based on their metabolic pathways, have been identified in their 
involvement in biohydrogenation, group A and group B bacteria (Table 2.2) (Bauman et al., 
2000). Both groups are required for complete biohydrogenation of PUFA in the rumen. But 
because of the smaller population of group B bacteria, group A products accumulate in the 
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rumen and can be absorbed by endogenous tissues of the animal (Palmquist et al., 2005). 
Kemp and Lander, 1984, grouped ruminal bacteria based on their respective metabolic 
pathways (Table 2.2). This was discovered by incubating pure cultures of ruminal bacteria 
with dietary FAs of ruminants (Kemp and Lander, 1984). Group A bacteria isomerize, 
shifting hydrogen bonds (cis to trans), and hydrogenate, adding hydrogen to remove double 
bonds, PUFAs. Group B bacteria further hydrogenate unsaturated FAs to form a saturated 
FA, stearic acid (Bauman et al., 2000). 
Table 2.2: Ruminal bacteria groups showing organisms, substrate and major products 
of group A and group B bacteria. 
Group Organism Substrate Major products 
A F2/6 (Ruminococcus 
albus) 
18:1; c-9, c-11, t-9, t-
11 
Not hydrogenated 
S2 (Butyrivibrio 
fibrisolvens) 
18:2; c-9, c-12 
18:3; c-9, c-12, c-15 
18 :1; t-11(+ t-10 with F2/6) 
18:1; t-11 (+ t-10 and 18:2; t-
11, c-15 with F2/6) 
B P2/2 (Fusocillus 
babrahomensis) 
18:1; c-9, c-11, t-9, t-
11 
Stearic acid (30% 
hydroxystearic acid with c-9 
and P2/2) 
T344 (Fusocillus sp.) 18:2; c-9, c-12 Stearic acid 
R8/5 (Gram-negative 
rod) 
18:3; c-9, c-12, c-15 18:1; c-15, t-15 (+c/t-13, 14 
and 16 with P2/2 and T344) 
Adapted from (Kemp and Lander, 1984)  
The biohydrogenation of dietary FAs in the rumen and the bacteria and enzymes involved in 
the process of the biohydrogenation of LA (C18:2), group A bacteria first isomerizes the 
double bond at c-12 to t-11, thus forming c-9, t-11 CLA (Figure 2.8). The double bond at c-9 
is then rapidly hydrogenated to form TVA (t-11 C18:1). The final step utilizes group B 
bacteria to further hydrogenate the t-11 bond, thus converting TVA to stearic acid (C18:0). A 
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membrane bound bacterial enzyme, LA isomerase, is responsible for the isomerization of cis-
9, cis-12 C18:2 and is highly specific for this substrate (Bauman et al., 2000, Khanal and 
Dhiman, 2004, Crumb, 2011). The biohydrogenation of linolenic acid (c-9, c-12, c-15, 
C18:3) occurs through a similar process: isomerization at c-12 forming c-9, t-11, c-15 C18:3 
and then hydrogenation of the double bonds at c-9 and c-15 to give transvaccenic acid, which 
is finally reduced at t-11 to give stearic acid. The biohydrogenation of ALA employ the exact 
same bacteria and enzymes as for LA biohydrogenation (Bauman et al., 2000, Khanal and 
Dhiman, 2004, Crumb, 2011). Although the processes are similar, no CLA isomer 
intermediate is formed during the biohydrogenation. The t10c12 CLA isomer is also 
synthesized in the rumen as an intermediate during the biohydrogenation of LA. This 
pathway is initiated by the enzyme c-9, t-10 isomerase, which forms t10c12 CLA.  The next 
reaction is the formation of t-10 C18:1 by c-12, t-11 isomerase. The final reaction is the 
reduction of the t-10 double bond to form a saturated FA, stearic acid (figure 2.8) (Khanal 
and Dhiman, 2004). 
 
2.5.3.2. Endogenous Conversion of CLA 
Evidence shows the production of c9t11 CLA isomer following the removal of two hydrogen 
atoms from 11-trans-octadecenoate (vaccenic acid) at carbon position 9 and 10 by Δ9-
desaturase enzyme, creating a carbon-carbon double bond at that position (Adlof et al., 2000, 
Miller et al., 2003). This forms a CLA FA as an intermediate in biohydrogenation of LA and 
ALA. The primarily source of Δ9-desaturase enzyme is in adipose tissue of beef cattle and in 
the mammary gland of lactating dairy cattle. This biosynthetic process accounts for 60-90% 
of the total CLA content in ruminant food products (Khanal and Dhiman, 2004). 
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Figure 2.8: Biohydrogenation of dietary FAs in the rumen (Khanal and Dhiman, 2004). 
LA, linoleic acid, CLA, conjugated linoleic acid.  
 
2.5.4. Sources of CLA 
CLA is found in beef and dairy products, such as milk and cheese and is produced in the 
rumen and udders of ruminant cows. The CLA content of milk fat and beef is dependent on 
the type of feed the cow receives (grazing, oil rich feed) and also on the breed of the cattle 
(Peterson et al., 2002). The concentration of CLA found in milk fat and dairy products was 
shown to increase in cows fed a diet rich in unsaturated FAs; oleic acid, LA and ALA 
(Collomb et al., 2006).  
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2.5.5. CLA and cell membranes 
Numerous studies show that when cells are treated with CLA isomers, they are incorporated 
into cell membranous lipids to the same extent as LA and AA (Moya-Camarena et al., 1999). 
The majority of the incorporated CLA were present in lipid rafts of the membranes. Unlike 
LA, which mainly occupies sn2-position of phospholipids, CLA incorporated in phospholipid 
fractions were found to occupy the sn-1 and sn-2 positions. These findings show that the 
incorporation profiles of CLA isomers differ significantly from that of LA, and have the 
potential to be incorporated twice as well as LA. This could lead to modifications in 
membrane function. CLA showed varying effects on desaturation index (18:1/18:0 and 
16:1/16:0) and Δ9-desaturase (Subbaiah et al., 2011). 
 
2.5.6. Effect of CLA in cancer cells 
It is well recorded that CLA plays a potentially beneficial role in the prevention of cancer 
development. Table 2.3 summarizes the major finding of CLA over the years with regard to 
carcinogenesis. The first incident recorded that FAs derived from beef reduced chemically 
induced tumour formation (Ha et al., 1987, Liu and Belury, 1998). Later findings revealed 
that treatment with CLA increased apoptosis (Evans et al., 2000, Ip et al., 2000), decreased 
cell proliferation (Cho et al., 2003), altered FA metabolism (Banni et al., 1999, Igarashi and 
Miyazawa, 2001) and modify components of the cell cycle (Belury, 2002). Furthermore, 
CLA treatment modulates markers of immunity (O’Shea et al., 2004) and eicosanoid 
formation (Banni et al., 2004, Belury, 2002). One or more of these pathways are responsible 
for the inhibitory properties CLA in carcinogenesis, with some tissue specificity and 
differences in isomer responses. 
 
 
 
 
33 
 
Table 2.3: The major findings on CLA and carcinogenesis. Reference   
↓ Mutagenesis mediated by liver S-9 from normal rats. 
↓ 7,12-dimethylbenzanthracene (DMBA) initiated papilloma in 
mice. 
↓ 12-O-tetradecanoyl-phorbol-13-acetate (TPA)-induced tumor 
promotion in mouse skin. 
↓Mammary cancer incidence by affecting LA metabolites 
↑ Apoptosis in 3T3-L1 pre-adipocytes. 
↑ Apoptosis and reduced the expression of bcl-2 in premalignant 
lesions. 
↓ Cancer cell growth by affecting FA metabolism. 
 
↓ DMH-induced colon carcinogenesis in rats. 
↑ Cytotoxicity of dRLh-84 rat hepatoma cells. 
↓ Cell proliferation and ErbB3 signalling in HT-29 human colon 
cell line. 
↑ p53 response that leads to the accumulation of pRb and cell 
growth arrest. 
↓Insulin like growth factor-II synthesis and downregulate IGF-IR 
signalling and the PI3K/Akt and ERK-1/2 pathways. 
↓ Membrane invasion by reducing type IV collagenase activities 
in the serum-free supernatant of SGC-7901.   
↓ Proliferation of PC-3cells via modulation of apoptosis and cell 
cycle control. 
↓ 5-lipoxygenase metabolite, 5-HETE, increasing apoptosis and 
decreasing cell proliferation. 
↑ Apoptosis via the mitochondrial pathway in rat hepatoma cells.  
↓ Expression of Bcl-2 proteins, increasing apoptosis. 
↓G1-S Progression in HT-29 Human Colon Cancer Cells. 
↑ Apoptosis in MDA-MB-231 breast cancer cells through 
ERK/MAPK signalling and mitochondrial pathway. 
↓breast cancer cell growth and invasion through ERalpha and 
PI3K/Akt pathways. 
(Pariza et al., 1979) 
(Ha et al., 1987) 
 
(Liu and Belury, 1998) 
 
(Banni et al., 1999) 
(Evans et al., 2000) 
(Ip et al., 2000) 
 
(Igarashi and Miyazawa, 
2001) 
(Park et al., 2001) 
(Yamasaki et al., 2002) 
(Cho et al., 2003) 
 
(Kemp et al., 2003) 
 
(Kim et al., 2003) 
 
(Yang et al., 2003) 
 
(Ochoa et al., 2004) 
 
(Kim et al., 2005) 
 
(Yamasaki et al., 2005) 
(Beppu et al., 2006) 
(Cho et al., 2006) 
(Miglietta et al., 2006) 
 
(Bocca et al., 2010) 
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↓ Viability and proliferation of HepG2 cancer cells in relation 
with cell cycle arrest and induction of apoptosis. 
↑apoptosis by c9, t11-CLA in human endometrial cancer RL 95-2 
cells via ERalpha-mediated pathway.  
(Melaku et al., 2012) 
 
(Wang et al., 2013) 
Adapted from (Terk, 2007) 
 
2.5.7. CLA and health implications 
Various studies show that some of the effects attributed to CLA include reduction in body fat 
and increased lean body mass, prevention of atherosclerosis, hypertension, different types of 
cancers and also increase immune function (Bhattacharya et al., 2006, McGuire and 
McGuire, 2000). Not many clinical studies have been conducted using CLA isomers to treat 
cancer in humans. However reports indicated that CLA may play a protective role against 
cancer development by inhibiting tumor initiation, promotion and progression. (Smedman 
and Vessby, 2001). The exact mechanisms on not well understood or well define, but a 
number of proposed mechanisms have been identified. These include: altering cell cycle 
events, induction of apoptosis, gene expression modulation via the activation of peroxisome 
proliferator activated receptors, lipid peroxidation, cell membrane structure and/or functional 
changes, and growth factor receptor signaling interference (Amarù et al., 2010).  
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3.1. Abstract 
Intracellular accumulation of peroxides and reactive oxygen species are established targets 
for cancer therapy intervention as they result in oxidative stress, which cause damage to 
cellular components such as lipids, proteins and DNA. Unsaturated fatty acids (FA’s), found 
at high concentrations in mammalian cell membranes, are highly susceptible to oxidative 
stress via the formation of lipid peroxides, hydroxyl radicals and reactive aldehydes. 
Conjugated linoleic acids (CLA, C18:2) are conjugated dienoic isomers of linoleic acid (LA, 
C18:2n6) found naturally in the meat and milk of ruminant animals, that are speculated to 
protect against oxidative stress. This study was aimed to determine the potential anti-
oxidative  properties of two CLA isomers, cis9-trans11 (c9t11) CLA and trans10-cis12 
(t10c12), CLA against iron (Fe
2+
)-induced microsomal lipid peroxidation compared to 
unconjugated 18-carbon (C18) FA’s, including mono-unsaturated fatty acids (MUFA) and 
polyunsaturated fatty acids (PUFA); containing two and three carbon-carbon double bonds. 
Iron-induced lipid peroxidation was measured by the production of malondialdehyde (MDA) 
as a thiobarbituric acid reactive substance (TBARS), utilising rat liver microsomes. 
Microsomes were pre-exposed (30 min) to the following FA’s: oleic acid (OA, C18:1n9) and 
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vaccenic acid (VA, C18:1n7), linoleic acid; c9t11 CLA, t10c12 CLA, α-linolenic acid (ALA, 
C18:3n3), and γ-linolenic acid (GLA, C18:3n6). Results, expressed as the 50% inhibitory 
concentration (IC50), indicated that vaccenic acid exhibited the highest (P<0.05) protection 
against lipid peroxidation followed by OA>LA>c9t11>t10c12>ALA with GLA exhibiting 
the weakest protection. The two CLA isomers did not differ from LA or ALA although the 
t10c12 CLA isomer tended to exhibit weaker protection than the c9t11 isomer. The number 
of double bonds plays a determining role of the FA against lipid peroxidation with GLA 
being to be significantly (P<0.05) more susceptible than LA. Apart from the number of 
double bonds, the position of the double bonds from the methyl end also seems to play a role 
in the susceptibility as VA exhibited a higher protection than OA, ALA more protective than 
GLA whilst c9t11 CLA exhibited a higher protection when compared to t10c12 CLA. 
 
3.2. Introduction 
Lipid peroxidation is a major mechanism of cellular damage in many biological systems. It 
involves a process whereby unsaturated FA’s react with cellular free radicals, are oxidized 
and form additional radical species and toxic by-products that can be harmful to the 
organism. Peroxidation reactions are accompanied by disturbances in cellular membrane 
structure and function (Esterbauer et al., 1982). Intracellular accumulations of lipid peroxides 
and products of lipid peroxidation are associated with cellular stress and linked to a variety of 
diseases, most notably heart disease and cancer. (Nakamura et al., 2012, Del Rio et al., 2005). 
The effects of lipid peroxides are 100-1000 times more potent than hydrogen peroxide and 
have shown to be strong inducers of cell death by inactivating protein tyrosine phosphatases, 
thus regulating the cellular communication of receptor tyrosine kinases (Conrad et al., 2010). 
Lipid peroxides are themselves unstable, and undergo additional decomposition to form a 
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complex series of compounds including highly reactive carbonyl compounds (Kulkarni et al., 
2013). 
Polyunsaturated fatty acids in the cell membrane are especially susceptible to lipid 
peroxidation when exposed to oxidizing agents, resulting in the formation of lipid peroxides 
(Song et al., 2000). This gains its importance from the ability of free radicals to initiate 
oxidative degradation of PUFA’s in cell membranes, resulting in membrane damage or 
production of lipid peroxides through a series of events or cascade (Palacios et al., 2003). 
PUFA peroxides are broken down resulting in the formation of malondialdehyde (MDA) and 
4-hydroxynonenal (HNE), which are found in most biological samples as products of lipid 
peroxidation, and has become one of the most widely reported components for the detection 
and estimation of oxidative stress effects on lipids (Niki et al., 2005). These aldehydes have 
been described to have potentially mutagenic effects on cells through interaction with nucleic 
acid bases of DNA and protein (Del Rio et al., 2005). 
Conjugated linoleic acids (CLA) are conjugated dienoic isomers of linoleic acid (LA) found 
mostly in the beef and dairy products of ruminant animals. This naturally occurring 
conjugated polyunsaturated fatty acid (PUFA) has been shown to possess anti-cancer, anti-
atherogenesis, anti-hypertensive and anti-obesity properties beneficial to human health 
(Bhattacharya et al., 2006). Extensive research has been conducted to elucidate the exact 
cancer protective mechanisms exhibited by CLA, one of which is the potential antioxidative 
role (McGuire and McGuire, 1999). 
Rat liver microsomes are commonly used as substrate to study lipid peroxidation in 
determining the pro- or anti-oxidant potential of compounds (Esterbauer et al., 1982). In this 
study the antioxidant potential of CLA isomers in a lipophilic rat liver microsomal model are 
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compared to other 18 carbon FA, representing the N9, N3 and N6 FA families, differing in 
number and position of double bonds. 
 
3.3. Materials and Methods 
3.3.1. Chemicals 
Sepharose 2B (Sigma-Aldrich CAS# 9050946), 0.01 M potassium phosphate buffer (K2HPO4 
and KH2PO4) pH 7.4 supplemented with 1.15% KCl made up with distilled water (dH2O), 
SDS solution (2% sodium dodecyl sulfate, 20 mM NaHCO3, 2 mM EDTA), bicinchoninic 
acid (BCA) protein assay reagent A (Pierce #23223), reagent B (4% CuSO4.5H2O), bovine 
serum albumin (BSA) standard 0.1 mg, trichloroacetic acid (TCA) reagent (containing 10% 
TCA, 1 mM EDTA and 125 µl BHT), 0.67% thiobarbituric acid (TBA), 2.5 mM FeSO4 
(Sigma-Aldrich CAS#7782630). All FA were acquired from Sigma-Aldrich: Linoleic acid 
(CAS# 60333), c9t11 CLA (CAS# 2540569), t10c12 CLA (CAS# 2420566), vaccenic acid 
(CAS# 506172), oleic acid  (CAS# 112801), γ-linolenic acid (CAS# 506363), α-linolenic 
acid (CAS# 463-40-1), 99% ethanol. 
 
3.3.2. Preparation of rat liver microsomes 
Ethical approval for the use of rodents for standard biochemical techniques was obtained 
from the MRC Ethics Committee for Research on Animals (ECRA) (Addendum 1). Rat liver 
homogenate fractions (S9 supernatant fraction) were prepared in 0.01M potassium phosphate 
buffer containing 1.15M KCl (pH = 7.4) from male Fischer rats with a body weight of 
approximately 200 g, according to a modified method described previously (Maron and 
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Ames, 1983). S9 fractions were aliquoted into sterile 50 ml falcon tubes and stored at -80 °C. 
All procedures were carried out on ice (4°C). 
Microsomes were prepared from the S9 fraction according to the method described 
previously (Gelderblom et al., 1984) by column (2.5 x 40 cm) chromatography using 
Sepharose 2B with potassium phosphate buffer (pH 7.4) as  eluent at 4 C. Microsomes, 
eluted in the void volume, were collected in 15 ml falcon tubes and stored at -80 C. 
 
3.3.3. Protein determination 
The microsomal protein concentration was determined by the Bicinchoninic Acid (BCA) 
protein assay (Kaushal and Barnes, 1986). Samples were diluted in SDS solution to denature 
proteins. A BSA standard was prepared ranging from 1 µg to 10 µg proteins to construct a 
standard curve. Absorbance readings were determined spectrophotometrically at 562 nm and 
the unknown protein concentration determined from the standard curve (Addendum 2). 
 
3.3.4. Determination of lipid peroxidation 
Antioxidative activity of two CLA isomers, c9t11 CLA and t10c12 CLA and other C18 FA; 
oleic acid (OA, C18:1n9), vaccenic acid (VA, C18:1n7), linoleic acid (LA, C18:2n6), α-
linolenic acid (ALA, C18:3n3) and γ-linolenic acid (GLA, C18:3n6) was monitored against 
iron (Fe
2+
)-induced lipid peroxidation utilizing rat liver microsomes.  The TBARS assay was 
performed by monitoring the formation of malondialdehyde (MDA) (Esterbauer and 
Cheeseman, 1990) (Addendum 3). Microsomes were dounced ten times using a tight glass 
dounce on ice and diluted to contain 1 mg protein per sample in each reaction tube. Stock 
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solutions of each FA were prepared in ethanol and serially diluted to the required 
concentration range (mM range; 0.2, 0.4, 0.6, 0.8 and 1 mM). The individual FA’s were 
incubated with microsomes at 37 °C for 30 minutes in a shaking water bath, Fe
2+
 (2.5 mM in 
distilled water) was added to induce lipid peroxidation (MDA formation). The samples were 
incubated at 37 °C for 1 hour in a shaking water bath after which, 2 ml TCA reagent 
(composition above) was added to each tube to stop the lipid peroxidation reaction. The 
samples were mixed by vortexing, centrifuged at 2000 rpm for 15 minutes. A volume of 2 ml 
of the supernatant was combined and mixed with 2 ml TBA solution in a clean reaction tube. 
The reaction tubes were tightly capped and incubated in a water-bath at 90 °C for 20 minutes 
and cooled to room temperature. Absorbance (optical density) was measured at 532 nm on a 
spectrophotometer, Jenway 67 Series, USA. Ethanol controls samples were included for each 
FA dilution in addition to the sample blanks containing the working phosphate buffer without 
the microsomes. 
Lipid peroxidation was expressed as nmol MDA equivalents per mg protein using the molar 
extinction coefficient of 1.56 x 10
5
 M
-1
 cm
-1
 at 532 nm for MDA (Esterbauer and Cheeseman, 
1990).  The percentage reduction of total lipid peroxidation by each FA was obtained from a 
untreated microsomal Fe
2+
 control sample and the 50% inhibitory concentration (IC50) were 
calculated using GraphPad Prism version 5.04 for Windows, GraphPad Software, (La Jolla, 
California, USA, www.graphpad.com). 
 
3.3.5. Statistical analyses 
Normality among the groups for the 2 parameters was investigated using the Kolmogorov 
Smirnoff Test. An ANOVA with two main effects (Concentration & FA group) and an 
 
 
 
 
59 
 
interaction effect was used to analyze each parameter. An interaction effect was included to 
test for a difference in slope (concentrations) for the FA’s. A significant interaction effect 
would indicate that the different concentrations reacted differently for all the FA’s. Least 
Squares Means were calculated, as well as the LSMeans differences and their 95% CI’s. Non-
parametric Kruskal-Wallis test group differences and Non-parametric Tukey-type test 
whether the groups differ at 5% level. Statistical analyses were performed with SAS v9.2 and 
statistical significance was considered at 5% (P<0.05). Inhibitory concentrations at 50% 
(IC50) were compared by ANOVA analyses. 
The TBARS IC50 data was analysed within a one-way ANOVA analysis, with multiple 
comparison of means using the Bonferroni method (equal variances assumed). Significance 
between the IC50 data of LA and t10c12 CLA was tested by a two-sample t-test. The Stata 11 
software (College Station, Texas, USA) was used for statistical analysis. 
 
3.4. Results 
TBARS assay was used to determine the antioxidant potential of the two major CLA isomers, 
c9t11 CLA and t10c12 CLA, and 5 other C18 unsaturated FA’s, representing FA’s with 1 
(VA and OA), 2 (LA) and 3 (ALA and GLA) double bonds. The dose response curve in 
Figure 3.1 illustrates the protection against lipid peroxidation presented by each FA at 
different concentrations. Interaction between percentage reduction and FA concentration 
revealed typical dose response effects which differ between the different FA’s (P<0.05), 
while IC50 of the Fe
2+
-induced lipid peroxidation was obtained for all the FA’s. The MUFA’s, 
VA and OA, differed significantly (P<0.05) from the other FA’s and provided the greatest 
protection against microsomal membrane lipid peroxidation. The PUFA’s showed 
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comparable protection against lipid peroxidation but showed significantly (P<0.05) lower 
antioxidant potential compared to the MUFA’s. 
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Figure 3.1: Dose response curves of FA susceptibility to Fe
2+-
induced lipid peroxidation. 
The dotted line represents 50% reduction in lipid peroxidation compared to untreated control. 
Percentage inhibition refers to the percentage of lipid peroxidation that had been reduced 
compared to the lipid peroxidation observed when microsomes were treated with a vector 
control (ethanol) in the presence of Fe
2+
. VA (vaccenic acid), OA (oleic acid), LA (linoleic 
acid), c9t11 CLA (cis9-trans11 conjugated linoleic acid), t10c12 CLA (trans10-cis12 
conjugated linoleic acid), ALA (α-linolenic acid), GLA (γ-linolenic acid). 
 
The IC50 obtained for each FA are presented in Table 3.1. The FA’s indicated in the 
significant difference column differed at the 5 % level (P<0.05). VA and OA exhibited the 
greatest reduction of lipid peroxidation (IC50; 0.11 and 0.19 mM, respectively) which differed 
significantly (P<0.05) from each other and all tested FA’s. LA and c9t10 CLA isomer 
produced a similar IC50 of 0.57 and 0.66 mM respectively, that significantly (P<0.05) differs 
* 
* * * 
* 
* 
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from VA, OA and GLA. The t10c12 CLA isomer and ALA produced a similar IC50 of 0.72 
and 0.80 mM respectively, with the CLA isomer differed significantly (P<0.05) from VA, 
OA, GLA and LA. GLA provided the least inhibition of lipid peroxidation, IC50; 0.99 µM, 
which was significantly (P<0.05) different when compared to VA, OA, both CLA isomers 
and LA.  
The FA’s with two double bonds showed interesting responses.  Linoleic acid showed a 
comparable protection than c9t11 CLA while a significant higher protection was noticed 
when compared to the t10c12 isomer. Alpha linolenic acid, containing 3 double bonds, 
Table 3.1: IC50 values reflecting the inhibition of Fe
2+
-induced lipid peroxidation of the 
individual fatty acids. 
Fatty Acid IC50 (mM) ± SD Significant difference  
Vaccenic acid (VA, C18:1n7) 0.11 ± 0.04 LA, c9t11, t10c12, ALA, 
GLA  
Oleic acid (OA, C18:1n9) 0.19 ± 0.05 LA, c9t11, t10c12, ALA, 
GLA 
Linoleic acid (LA, C18:2n6) 0.57 ± 0.06 VA, OA, GLA, ALA 
cis9-trans11 CLA (c9t11, C18:2) 0.65 ± 0.13 VA, OA, GLA 
trans10-cis12 CLA (t10c12, C18:2) 0.72 ± 0.03 VA, OA, GLA, LA 
α-Linolenic acid (ALA, C18:3n3) 0.81 ± 0.13 VA, OA, LA 
γ-Linolenic acid (GLA, C18:3n6) 0.99 ± 0.07 VA, OA, LA, c9t11, 
t10c12 
IC50 values are the means ± SD of two repetitions. FA’s are presented with common name, 
abbreviation and chemical notation. Significant difference is indicated when P<0.05. VA 
(vaccenic acid), OA (oleic acid), LA (linoleic acid), c9t11 CLA (cis9-trans11 conjugated 
linoleic acid), t10c12 CLA (trans10-cis12 conjugated linoleic acid), ALA (α-linolenic acid), 
GLA (γ-linolenic acid). 
 
 
 
 
 
62 
 
showed a comparable protection against lipid peroxidation with t10c12 CLA but differed 
significantly from t10c12 CLA, LA and the MUFAs. Except for ALA, GLA differed 
significantly from all the other FA’s and provided the least protection against microsomal 
lipid peroxidation. 
 
3.5. Discussion 
The microsomal model used provides a biological system to study the direct effect of the FA 
on Fe
2+
-induced lipid peroxidation (Hochstein and Ernster, 1963). As a membranous 
structure lipid model, the microsomes can be subjected to lipid peroxidation when treated 
with Fe
2+
 to investigate the stimulating or protecting effect of unsaturated FA (Wilhelm, 
1990). The oxidative potential is given by the ability of FA to be oxidized by free radicals 
and subsequently form lipid peroxides. It would therefore be of interest to study the 
interactions of different FA in the microsomal model regarding their possible antioxidant or 
pro-oxidant potencies. The purpose of this study was to investigate the protective and 
therefore antioxidant effect of two CLA isomers, c9t11 CLA and t10c12 CLA, against Fe
2+
-
induced lipid peroxidation.  Their protective effect was subsequently compared to selected 
C18 FA’s containing 1 (VA and OA), 2 (LA) and 3 (ALA and GLA) double bonds 
representing monounsaturated fatty acids (MUFA’s) and PUFA’s. 
 Microsomes, pre-treated for 30 minutes with different concentrations of OA, VA, LA, c9t11 
CLA, t10c12 CLA, ALA and GLA, revealed distinguishable variability in the antioxidant 
potential against Fe
2+
-induced lipid peroxidation.  The greatest protection was obtained by 
the MUFA’s i.e. VA and OA which is in accordance with previous studies and known 
properties of OA. It was indicated that these MUFA’s, are less susceptible to oxidation and 
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have lower pro-inflammatory activity when exposed to conditions resulting in oxidative 
stress (Lee et al., 1998). Although MUFA’s showed the highest protection against lipid 
peroxidation than the PUFA’s in this experiment, a slight difference in the protective activity, 
depending on the concentration used, exists between VA and OA. At low concentrations VA 
appears to be more protective than OA, hence the slight lower IC50 value obtained.   A type of 
plateau effect is reached at higher concentrations which could point towards a pro-oxidative 
effect above where no additional protection is obtained. 
PUFA’s are known to be more vulnerable to lipid peroxidation or rancidity than MUFA’s, as 
they contain two or more double bonds, which are separated by methylene bridges (-CH2-) 
that hold an especially reactive hydrogen atom (Song et al., 2000). To explain the relationship 
between MUFA and PUFA activity against lipid peroxidation, the lipid peroxidation can be 
appraised, the initial step is the subtraction of a hydrogen atom from the double bond by an 
hydroxyl or hydroperoxyl radical to produce lipid radicals (Halliwell and Chirico, 1993). 
Thus, with MUFA only one free hydrogen atom exists for interaction, therefore they are less 
susceptible to lipid peroxidation as compared to PUFA’s and therefore may acts as 
scavengers of free radicals, exhibiting antioxidant potential.  
The current study showed that PUFA is more susceptible to oxidation and therefore less 
protection was achieved against lipid peroxidation. Of the PUFA containing 2 double bonds 
the CLA isomers and LA exhibited a higher protection than ALA and GLA (each containing 
3 double bonds). Linoleic acid showed the highest protection against lipid peroxidation of the 
PUFA’s containing 2 double bonds. The difference between the PUFA’s with 2 doubles is the 
position of the double bond relative to the methyl end. LA has the double bond at carbon 
position 6 (C18:2n6), followed by c9t11 CLA and t10c12 CLA isomers, with the double 
bonds at carbon position 11 and 12, respectively. ALA and GLA, containing 3 double bonds 
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produced higher IC50 values and therefore provide less protection and lower antioxidative 
potential against Fe
2+
-induced lipid peroxidation than the C18:2 FAs. These FA contain 3 
double bonds with the first double bond at carbon position 3 and 6, respectively with ALA 
showing a slight greater susceptibility to lipid peroxidation than GLA. This indicates an 
apparent relationship between the position of the first double bond closest to the methyl end 
of the FA chain and the protection against lipid peroxidation. 
Both the CLA isomers tend to exhibit a weaker response regarding the protection against 
lipid peroxidation when compared to LA. The c9t11 isomer exhibited a similar but weaker 
protection against lipid peroxidation as compare to LA while the t10c12 isomer exhibited 
significant weaker response with a similar activity to ALA (Table 3.1). Confounding 
evidence on the antioxidant potential of CLA exist in literature. CLA (isolated isomers and 
mixtures) showed an antioxidative effect when treated with a stable DPPH free radical (2, 2-
diphenyl-1-picrylhydrazyl), by a direct free radical scavenging (Ali et al., 2012.). In another 
study, dietary CLA (0.75% and 1.5% CLA mixtures diet) was reported  not to directly affect 
the oxidative status in Broiler chickens, although hepatic catalase activity increased which 
may affect hepatic antioxidant defence system and lipid metabolism by increasing hepatic 
peroxisomal activity (Ko et al., 2004). To the contrary, c9t11 CLA was reported to increase 
the susceptibility of breast cancer cells to undergo lipid peroxidation (Devery et al., 2001). 
The levels tend to increase the vulnerability of the cells above the normal oxidative stress 
levels and exhibiting a cytotoxic effect that would contribute to the anti-tumour effects of 
CLA. These studies suggest that CLA may possibly scavenge free radicals present in a 
healthy system, but due to its polyunsaturated nature, are more susceptible to lipid 
peroxidation, which may positively affect the anti-tumour mechanism of CLA (Stachowska et 
al., 2008). Although no significant difference between c9t11 CLA and t10c12 CLA isomers 
was found, they did however show minor difference in the protection against lipid 
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peroxidation when compared to LA and ALA i.e. less protective that LA and more protective 
than ALA.  The least reduction of Fe
2+
-induced lipid peroxidation was found in GLA treated 
samples. This indicates that GLA offers little protection against lipid peroxidation. Many 
studies highlight the lipid peroxidation promoting ability of GLA in cancer cells and, similar 
to the t10c12 CLA isomer, this mechanism plays a role in GLA cytotoxicity (Ramanathan et 
al., 1994 , Ge et al., 2009).  
The current study investigated, for the first time, the comparative antioxidant properties of 
different classes of mono- and polyunsaturated fatty acids. Each individual unsaturated FA 
reacts differently in response when exposed to free radicals and therefore should be tested 
separately  with respect  to dietary recommendations and should not be generally categorized  
solely as MUFA’s and PUFA’s, but to extend them to their individual effect related to 
oxidative stress (Di Nunzio et al., 2011). It became evident that a relationship exists between 
the number of double bonds, the position of the first double bond closest to the methyl group 
and susceptibility to lipid peroxidation. It is evident that the more double bonds present, the 
more susceptible to lipid peroxidation. And the closer the first double bond is to the methyl 
end of the FA, the less susceptible to lipid peroxidation. These two factors clearly influence 
the degree of reduction in lipid peroxidation. 
In the present study, MUFA exhibited the highest protection against lipid peroxidation, while 
depending on the CLA isomer; it showed similar antioxidant potential to LA and ALA. 
Therefore, CLA membrane incorporation and influence of cellular events, such as cell 
proliferation and apoptosis, need to be evaluated to fully assess the mechanism of 
chemoprevention of CLA. 
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4.1. Abstract 
Positional and geometric isomers of linoleic acid (LA), collectively called conjugated linoleic 
acid (CLA), are found in the meat and milk from ruminant animals. There are anticancer 
properties of CLA that have been studied extensively. Although the exact mechanisms of 
action are not yet known, CLA has shown to affect apoptosis and cell proliferation, with 
some isomer and tissue differences. This study aimed to determine the effect of two CLA 
isomers, cis9-trans11 (c9t11) and trans10-cis12 (t10c12), on the growth and survival indices 
of HepG2 human hepatocarcinoma cells. Cytotoxicity, cell viability, apoptosis and cell 
proliferation was measured after 48 hour treatment to determine the effect of the CLA 
isomers, LA and α-linolenic acid (ALA) on these parameters. The c9t11 CLA isomer showed 
greater cytotoxicity and an increase in apoptosis compared to t10c12 CLA (all significant, 
P<0.05). Both CLA isomers significantly reduced cell proliferation (P<0.05). The activity of 
c9t11 was comparable to the omega 3 fatty acid, ALA, for all tested parameters, and 
exhibited a significantly higher activity than LA. Differences existed in anti-proliferative 
properties of between the two CLA isomers; however both are effective in reducing cell 
 
 
 
 
72 
 
proliferation a key effect in chemoprevention. The activity of c9t11 is linked to apoptosis and 
cytotoxicity, illustrated in this study, but t10c12 possess a different mechanism that involved 
cell cycle arrest and senescence. 
 
4.2. Introduction 
Conjugated linoleic acid (CLA) was originally described as an anticarcinogen isolated from 
fried ground beef (Ha et al., 1987) and was later discovered to have additional health benefits 
such as: protecting against obesity (Miner et al., 2001, Kennedy et al., 2010), atherosclerosis 
(Mooney et al., 2012) and diabetes (Noto et al., 2006, Moloney et al., 2004). To date, in vivo 
animal studies as well as in vitro tissue culture studies have demonstrated CLA to have 
beneficial effects as a chemo-preventative measure, though extensive research is required 
before it can be used as such. CLA has shown to be an effective agent for reducing the 
growth and development of a variety of cancer cell types, which are substantiated by 
extensive research. High CLA levels (c9t11 and t10c12 CLA isomers) reduced cell growth, 
induced apoptosis and also modulated FA metabolism of mammary cells (Keating et al., 
2008) with similar responses seen in colon cancer cells (Cho et al., 2003), prostate cancer 
cells (Ochoa et al., 2004) and liver cancer cells (Melaku et al., 2012). However, the isomer 
and tissue specific anticancer mechanisms of CLA are yet to be fully defined as some studies 
have shown differences in activity between the two CLA isomers (Melaku et al., 2012). 
Phosphoinositide 3-kinase/Protein kinase B (PI3K/Akt) cascade, which promotes cell 
proliferation, glucose metabolism and survival, is  down regulated in mammary cells by 
addition of CLA – 1:1 c9t11: t10c12 CLA mixture (Bocca et al., 2010). The same mechanism 
was found to prevail  in colon cancer cells (HT29), but included down regulation of ErbB3 
signalling (Cho et al., 2003), decrease in insulin-like growth factor (IGF) II synthesis and 
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down-regulation of extracellular signal-regulated kinase-1/2 pathway and IGF-I receptor 
signalling (Kim et al., 2003). Moreover, CLA has shown to inhibit the growth of cancer cells 
through induction of p21 (CIP1/WAF1), a cyclin-dependent kinase inhibitor, thereby 
regulating the cell cycle progression at G1 and S phase (Lim et al., 2005). 
The aim of this study was to determine the effect of the CLA isomers, c9t11 CLA and t10c12 
CLA, ability to prevent the survival and growth  a of human liver HepG2 cancer cell line  as 
compared to LA and ALA by measuring cytotoxicity, cell viability, cell proliferation and 
apoptotic indices. 
 
4.3. Materials and Methods 
4.3.1. Chemicals 
Promega (South Africa) assay kits: CellTiter-Glo® Luminescent Cell Viability assay (Cat # 
G7571), Caspase-Glo® 3/7 assay (Cat# ZZG8092), Roche Cell Proliferation ELISA, BrdU 
(Cat# 11669915001). All FA’s were acquired from Sigma-Aldrich (South Africa): linoleic 
acid (Cat# 60333), conjugated linoleic acids c9t11 (Cat# 2540569), t10c12 (Cat# 2420566), 
α-linolenic acid (Cat# 463401), 99 % Ethanol (Sigma-Aldrich Cat# 64175), Dulbecco’s 
phosphate buffered saline (DPBS; pH = 7.0 - 7.2, Cat# 14190250). Culture media: Eagle’s 
Minimum Essential Medium (Lonza Cat# BE12-125F) supplemented with 10 % fetal bovine 
serum (FBS), 1 % non-essential amino acids, 1 % pyruvate and 1 % L-glutamate. Treatment 
media: Eagle’s Minimum Essential Medium supplemented with 5 % FBS, 1 % non-essential 
amino acids, 1 % pyruvate and 1 % L-glutamate. Trypsin/EDTA (Lonza Cat# CC5012), 
Hanks' Balanced Salt Solution (HBSS) (Lonza Cat# 10-508F), Phenolphthalein (Analar 
37188), 0.1M NaOH, Fatty acid free bovine serum albumin (BSA, Roche Cat# 70335128) 
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4.3.2. Maintenance of Hep G2 cell culture 
HepG2 cells were obtained from ATCC and cultured in 75 cm
3
 flasks with culture medium 
(above) and sub-cultured at 80% confluency. Culture medium was replaced when necessary. 
 
4.3.3. Preparation of fatty acids for treatment 
Stocks (10 mM) of the individual FAs were coupled with FA-free BSA for treatment of cell 
cultures, according to a previously described method (Ellsworth et al., 1986). Briefly, the 
required FAs were measured relative to the amount needed to make up the final concentration 
and mixed with 1 ml pure ethanol and 1 mg phenolphthalein. A 0.1M NaOH solution was 
used to titrate the mixture and solvent was evaporated on a 37°C heating block under N2 gas. 
The FA salt was then dissolved in DPBS, half the volume required to make the 10 mM 
solution. A BSA solution (5 mM) was prepared in DPBS, and added to the respective FA salt 
solution in equal volume to make up a 10 mM FA stock solution required for treatment of the 
cells. 
 
4.3.4. Fatty acid treatment of Hep G2 cells 
The respective 10 mM FA stock solutions prepared as described above, were diluted with 
treatment media containing 5% FBS (above) to the required concentrations ranging between 
0.01 mM and 0.8 mM. Hep G2 cells were seeded at 20000 cells per well in a 96 well 
microtitre plate and allowed to attach for 24 hours in culture media (above). Thereafter, the 
culture media was removed and replaced with 200 µl treatment media containing the FA 
BSA solution mentioned above at the required concentration between 0.01 mM and 0.8 mM. 
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Cells were then incubated for 48 hours and different growth parameters monitored using the 
appropriate assay kits. 
 
4.3.5. Cell culture assays 
4.3.5.1. Cytotoxicity 
Cytotoxicity was determined by measuring lactate dehydrogenase (LDH) release following 
48 hour treatment with FA at concentrations 0.05, 0.1, 0.2, 0.4 and 0.8 mM. LDH was 
measured using the Promega CytoTox 96® Non-Radioactive Cytotoxicity Assay according to 
the manufacturer’s instructions. Cells were seeded in white 96 well plates; untreated cells 
were used as positive control to calculate the percentage of viable cells in the experiment. 
LDH was determined by luminescence, recorded using a Biotek Synergy Mx 
Monochromator-Based Multi-Mode Microplate Reader (USA). 
 
4.3.5.2. Cell viability 
Cell viability was determined by monitoring ATP production using the Promega CellTiter-
Glo
®
 Luminescent Cell Viability assay. Cells were seeded in white 96 well plates and treated 
with FA at 0.01, 0.05, 0.1, 0.2, 0.4 and 0.8 mM for 48 hours. Untreated cells were used as 
positive control to calculate the percentage of viable cells in the experiment. ATP was 
determined according to the manufacturers’ kit instruction. Luminescence was recorded using 
a Biotek Synergy Mx Monochromator-Based Multi-Mode Microplate Reader (USA). 
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4.3.5.3. Cell proliferation  
Cell proliferation was determined by DNA incorporation of BrdU using the Roche Cell 
Proliferation ELISA, BrdU. After 48 hour treatment with FA at 0.01, 0.05 and 0.2 mM 
concentrations, 10 µl BrdU labelling solution was added to each well and incubated for 2 
hours at 37°C. BrdU was determined according to the manufacturers’ kit instructions by 
luminescence using a Biotek Synergy Mx Monochromator-Based Multi-Mode Microplate 
Reader (USA). 
 
4.3.5.4. Apoptosis  
Caspase 3, as an indicator of apoptosis, was measured using the Promega Caspase-Glo
®
 3/7 
assay. Cells were seeded in 96 well plated and treated with FA at 0.1, 0.2, 0.4 and 0.8 mM 
concentrations for 48 hours. Caspase 3 was determined according to the manufacturers’ kit 
instruction. Luminescence was recorded using a Biotek Synergy Mx Monochromator-Based 
Multi-Mode Microplate Reader (USA). 
 
4.3.6. Statistical analyses 
All experiments were carried out in quadruplicate and repeated for consistency. The 
statistical significance between groups was assessed by analysis of variance (ANOVA). All 
statistical analyses were performed with SPSS and the IC50
 
for each assay determined using
 
GraphPad Prism version 5.04 for Windows, GraphPad Software, (La Jolla, California, USA, 
www.graphpad.com). 
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4.4. Results 
4.4.1. Cytotoxicity 
Percentage cytotoxicity, as determined by LDH release, of HepG2 cells, following treatment 
with different concentrations of c9t11 CLA, t10c12 CLA, LA and ALA for 48 hours (Figure 
4.1). ALA showed the greatest cytotoxicity. CLA isomers and LA were comparable below 
0.2 mM however, c9t11 CLA showed greater cytotoxicity than t10c12 CLA and LA at higher 
concentrations. Descriptive statistics comparing differences between concentrations showed 
that the c9t11 CLA differed significantly (P<0.05) from; the t10c12 CLA isomer at 0.8 mM, 
LA at 0.4 mM and 0.8 mM, and ALA at 0.2, 0.4 and 0.8 mM. The t10c12 CLA isomer 
differed significantly (P<0.05) from; LA at 0.2 and 0.4 mM and ALA at 0.2, 0.4 and 0.8 mM. 
LA differed significantly from ALA at 0.1, 0.2, 0.4, and 0.8 mM. 
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Figure 4.1: Percentage cytotoxicity as determined by LDH release on Hep G2 cancer 
cells following treatment with c9t11 and t10c12 CLA isomers, LA and ALA for 48 
hours. Percentage cytotoxicity is presented as a mean (n=4) percent of untreated controls 
(with standard error bars). The broken line represents 50 % reduction in cell proliferation. 
The * denotes significantly different (p<0.05) activity to other FAs at the same concentration 
(0.2 mM). LDH, lactase dehydrogenase; FA, fatty acid; LA, linoleic acid; ALA, alpha-
linolenic acid; CLA, conjugated linoleic acid; NA, not available, IC50 was not reached within 
the tested concentration range for LA and t10c12 CLA. 
 
4.4.2. Cell Viability  
Percentage viability of HepG2 cells following treatment with different concentrations of 
c9t11 CLA, t10c12 CLA, LA and ALA for 48 hours is illustrated in Figure 4.2. Cell viability 
decreased in a dose-dependent manner in all FA treatment groups. Comparing the slopes for 
each treatment group, all FA produced statistically significant (P<0.05) slope differences 
response, indicating that all treatment FAs responded differently. The median inhibitory 
concentrations (IC50 ± SD) for c9t11 CLA, t10c12 CLA, LA and ALA were calculated to be 
0.309 ± 0.063, 0.679 ± 0.035, 0.69 ± 0.064, and 0.374 ± 0.035 mM respectively. Comparing 
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the IC50
s
 revealed no significant difference between treatment with c9t11 CLA and ALA and 
between treatment with t10c12 and LA. These two groups (c9t11 CLA; ALA and t10c12 
CLA; LA) differed significantly (P<0.05), indicating that c9t11 CLA produced a significantly 
greater cytotoxic effect than t10c12 CLA.  
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Figure 4.2: Viability (ATP) of Hep G2 cancer cells following treatment with c9t11 and 
t10c12 CLA isomers, LA and ALA for 48 hours. Percentage viability is expressed as mean 
(n=4), with SEM error, percentage of treated against untreated controls. The horizontal 
dashed line denotes 50% reduction in cell viability. The vertical dashed line represents 0.2 
mM, the highest tested concentration at which all FA are below the IC50, and common 
concentration for all tested parameters. FA, fatty acid; LA, linoleic acid; ALA, alpha-
linolenic acid; CLA, conjugated linoleic acid 
 
4.4.2. Cell proliferation  
Cell proliferation was measure as a percentage of DNA incorporated BrdU present following 
treatment with the respective FA concentrations for 48 hours (Figure 4.3). The treatment 
concentrations were selected on the basis below the cell viability IC50, where cells are still 
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actively producing ATP. Overall, a dose dependent reduction in cell proliferation was 
observed with all FA treatments, with c9t11 CLA and ALA showing the highest and LA the 
least response. When comparing the means, a significant difference was found between 
concentrations (P<0.05) but not between the various FAs, although LA produced a weaker 
response. Comparing the slopes of Figure 4.3, LA was significantly different (P<0.05) from 
c9t11 CLA, t10c12CLA and ALA. No significant difference was found between t10c12 CLA 
and c9t11 CLA. 
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Figure 4.3: Percentage cell proliferation on Hep G2 cancer cells following treatment 
with c9t11 and t10c12 CLA isomers, LA and ALA for 48 hours. Percentage cell 
proliferation is presented as a mean (n=4) percent of untreated controls (with standard error 
bars). The broken line represents 50 % reduction in cell proliferation. The * denotes 
significantly different (p<0.05) activity to other FAs at the same concentration (0.2 mM). FA, 
fatty acid; LA, linoleic acid; ALA, alpha-linolenic acid; CLA, conjugated linoleic acid; NA, 
not available, IC50 was not reached within the tested concentration range. 
  
* 
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4.3. Apoptosis  
Apoptosis was measured by the fold increase in caspase 3 levels of Hep G2 cells following 
treatment with the two CLA isomers, LA and ALA when compared to untreated control after 
48 hours (Figure 4.4). A dose-dependent fold increase in caspase 3 was found for all FA 
groups. Pairwise differences between the means of each FA treatment were significant 
(P<0.05). Comparing the slopes revealed that t10c12 CLA treatment differed significantly 
(P<0.05) from c9t11 CLA, LA and ALA. At low concentrations (0.1 and 0.2 mM) t10c12 
CLA and LA had a similar effect on apoptosis but at higher concentrations (0.4 and 0.8 mM) 
LA response was greater. There is statistical significance (P<0.05) between t10c12 CLA and 
c9t11 CLA induction of apoptosis at all concentration. 
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Figure 4.4: Apoptotic effect of c9t11 and t10c12 CLA isomers, LA and ALA on Hep G2 
cancer cell line. Fold increase refers to the increase in caspase 3 following 48 hour treatment 
compared to untreated controls. Plotted are the means (n=4) with standard error. The broken 
line indicates 0.2 mM, which is below the apoptosis IC50 for all treatments. FA, fatty acid; 
LA, linoleic acid; ALA, alpha-linolenic acid; CLA, conjugated linoleic acid 
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4.5. Discussion 
The purpose of this study was to evaluate the effect of two CLA isomers, c9t11 CLA and 
t10c12 CLA, in comparison to LA and ALA on HepG2 liver cancer cell survival. These FAs 
are 18 carbons in length and differ only in the position of their double bond and geometric 
configuration, with the exception of ALA which is an omega 3 FA with three double bonds. 
The measuring of cell growth parameters, including cytotoxicity, viability, cell proliferation 
and apoptosis, are essential in the development of cancer. These factors are amongst the most 
common known targets for assisting in developing an effective chemo-preventive or 
chemotherapeutic agent (Hanahan and Weinberg, 2011). 
Cytotoxicity was measured by the release of LDH by dead cells. The analysis showed that 
ALA was the most cytotoxic of the tested FA, with an IC50 of 0.23 mM, followed by the 
c9t11 CLA isomer, IC50 0.53 mM. The t10c12 CLA isomer and LA were less cytotoxic and 
their respective IC50 were outside the tested FA concentration range (i.e. IC50 > 0.8 mM). 
Cell viability decreased dose-dependently for all FA; however two groupings could be 
distinguished.  The c9t11 CLA isomer and ALA showed the greatest decrease in cell viability 
with the lowest IC50 (0.309±0.063 and 0.374±0.035 mM, respectively), whereas t10c12 CLA 
isomer and LA showed a weaker response with concomitant higher IC50 (0.679±0.035 and 
0.69±0.064 mM, respectively). 
Various studies have demonstrated that the cytotoxic effect of the two major CLA isomers, 
c9t11 CLA and t10c12 CLA, are different and tissue specific. The c9t11 CLA was more 
cytotoxic than t10c12 CLA in rat hepatic stellate cells (HSC-T6) (Yun et al., 2008) whereas 
in mammary cells (MCF-7) the effects was greater for t10c12 CLA compared to c9t11 CLA 
(Amarù and Field, 2009). One of the proposed mechanism of CLA against the growth of 
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cancer cells are the modulation of cell cycle events such as inhibition of cell proliferation and 
induction of apoptosis (Kelley et al., 2007, Melaku et al., 2012). 
The c9t11 CLA isomer and ALA displayed the greatest inhibition of cell proliferation and a 
consequential increase in apoptosis dose dependently. These findings are consistent with 
previous studies on ALA and omega-3 FAs as being cytotoxic, inhibiting cell proliferation 
and inducers of apoptosis on SP 2/0 mouse myeloma cells at concentrations of 5 µg/ml 
(Sravan Kumar and Das, 1997). ALA has shown to positively affect apoptosis by inhibiting 
the PI3K (phosphoinositide-3-kinase) pathway and Bcl-2 (B-cell lymphoma 2) expression in 
BCR-ABL positive leukemic cells (Beaulieu et al., 2011) . Bcl-2 protein family are a major 
tumour suppressor gene family. It is well known that an increase in Bax/Bcl-2 ratio, both of 
which belong to the Bcl-2 family of genes, promotes apoptosis of cancer cells (Salakou et al., 
2007). Regarding nuclear morphology and flow cytometric analysis, c9t11CLA inhibited 
viability and triggered apoptosis through increased expression of caspase-3 as well as the 
ratio of Bax/Bcl-2 genes (Wang et al., 2013). 
The t10c12 CLA isomer and LA were similar regarding their effect on cytotoxicity and 
cell viability, while at concentrations below 0.2 mM, cell proliferation and apoptosis were 
similar as well. However, LA increased apoptosis whereas t10c12 CLA reduced cell 
proliferation at concentrations greater than 0.2 mM. The collective effects observed at 0.2 
mM are shown in Table 4.1. This concentration (0.2 mM) was selected to show how the 
two CLA isomers differ from each other as well as their comparative effect to LA and 
ALA. The concentration of 0.2 mM was selected because it is below the IC50 for all FA. 
At concentrations greater than the cell viability IC50, cytotoxicity is a cofounding factor. 
Above the IC50, necrosis would interfere with apoptosis and cell proliferation analyses; 
there would be an insufficient amount of viable cells in the assay to acquire an accurate 
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measurement of these parameters. At 0.2 mM the c9t11 CLA isomer had comparable 
effects to ALA for all tested parameters i.e. reduced cell viability, inhibition of cell 
proliferation an increased apoptosis. The t10c12 CLA isomer was comparable to LA with 
regard to cell viability and apoptosis, but showed greater inhibition of cell proliferation 
similar to that of c9t11 CLA and ALA.  
 
Table 4.1: Comparing growth parameters of Hep G2 cells following treatment with two 
CLA isomers, LA and ALA for 72 hours at 0.2mM concentration. 
Cell parameters LA t10c12 c9t11 ALA 
Cytotoxicity (%) 
Cell Viability (%) 
7.26±0.42
a
 
72.61±3.19
a
 
16.08±3.65
b
 
82.32±2.81
b
 
12.36±1.09
ab
 
63.99±4.76
c
 
51.18±4.11
c
 
58.21±1.28
c
 
Cell proliferation (%) 72.61±8.4
a
 39.44±1.73
b
 32.46±7.56
b
 35.58±20.59
b
 
Apoptosis (fold increase) 2.97±0.15
a
 2.11±0.12
b
 11.65±0.39
c
 9.53±0.23
d
 
Means with SD are compared within tested parameter. Differing superscript letters 
indicate significant difference (P<0.05). LA, linoleic acid; ALA, alpha-linolenic acid; 
CLA, conjugated linoleic acid. 
 
Therefore, at a concentration of 0.2 mM distinguishable differences were observed between 
c9t11 CLA and t10c12 CLA (Table 4.1). The c9t11 CLA isomer reduced cell viability and 
increased apoptosis more effectively than t10c12 CLA even though there is no difference in 
the inhibition of cell proliferation.  These findings suggest that t10c12 CLA may possess 
anticancer properties that to a lesser extent involve apoptosis and more actively involve 
effects on cell growth involving cell cycle arrest and senescence.  Of interest is that, t10c12 
CLA was shown to be a greater inhibitor of the genes regulating cell cycle and growth than 
c9t11 CLA (Kelley et al., 2007). 
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Initially, it was thought that the anti-tumour properties of CLA were reduction of cell 
viability and inhibition cell proliferation, and increasing apoptosis (Khanal, 2004). In the 
present study, clear differences existed in the activity between the two CLA isomers, c9t11 
CLA and t10c12 CLA were shown, which are substantiated in previous findings (Kelley et 
al., 2007, Khanal, 2004). A study showed that different anti-tumour mechanisms exist for 
these two isomers when CLA decreased prostate cancer cell proliferation. The t10c12 CLA 
isomer increased apoptosis by decreasing bcl-2 gene expression and increasing p21
WAF1/Cip1
 
mRNA, whereas c9t11 CLA increased apoptosis and decreased cell proliferation by 
increasing 5-lipoxygenase (5-LOX) expression and cyclooxygenase-2 (COX-2) protein level, 
which are involved in formation of arachidonic acid-derived eicosanoids (Ochoa et al., 2004). 
Loss of cellular growth control and cellular senescence are two hallmarks of cancer described 
in previous studies (Hanahan and Weinberg, 2011). These factors are critical for cancer 
development. Cellular senescence has been defined by the loss of proliferative potential, 
losing the cells ability to proliferate. When a growth signal is reintroduced it typically 
stimulates cellular hypertrophy and not proliferation (hyperplasia). Therefore cells increase in 
cell size and not cell number. This should be distinguished from cell cycle arrest, which is 
avoided by cancer cells to continue proliferation despite unfavourable conditions 
(Blagosklonny, 2011). Some tumour suppressors (Rb and p16) cause cell cycle arrest while 
others (PTEN and TSC1/2) inhibit the growth promoting mTOR pathway involved in 
senescence (Blagosklonny, 2011). The p53 protein is the only identified tumour suppressor 
that both causes cell cycle arrest and inhibit senescence (Li et al., 2012). The t10c12 CLA has 
been shown to inhibit cell proliferation via the p53 pathway (Kemp et al., 2003). Further 
studies should study the effect of CLA isomers on tumour suppressor genes, cyclin dependent 
kinases and checkpoint proteins to fully understand the different anticancer properties of 
CLA isomers.  
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It is not known at present what the interaction of the different CLA isomers are with the 
different fatty acid classes including saturated (SATS), monounsaturated (MUFA) and the 
polyunsaturated fatty acids (PUFAs) within the cell.  As many of these FA plays an important 
role in cell biology the modulating effect of the different CLA isomers are therefore on 
interest.    
 
 
 
 
87 
 
4.6. References 
AMARÙ, D. L. & FIELD, C. J. 2009. Conjugated Linoleic Acid Decreases MCF-7 Human 
Breast Cancer Cell Growth and Insulin-Like Growth Factor-1 Receptor Levels. 
Lipids, 44, 449-458. 
BEAULIEU, A., PONCIN, G., BELAID-CHOUCAIR, Z., HUMBLET, C., BOGDANOVIC, 
G., LOGNAY, G., BONIVER, J. & DEFRESNE, M. P. 2011. Leptin reverts pro-
apoptotic and antiproliferative effects of alpha-linolenic acids in BCR-ABL positive 
leukemic cells: involvement of PI3K pathway. PloS one, 6, e25651. 
BLAGOSKLONNY, M. V. 2011. Cell cycle arrest is not senescence. Aging and Leisure 
Living, 3, 94–101. 
BOCCA, C., BOZZO, F., CANNITO, S., COLOMBATTO, S. & MIGLIETTA, A. 2010. 
CLA reduces breast cancer cell growth and invasion through ERalpha and PI3K/Akt 
pathways. Chemico-biological interactions, 183, 187-93. 
CHO, H. J., KIM, W. K., KIM, E. J., JUNG, K. C., PARK, S., LEE, H. S., TYNER, A. L. & 
PARK, J. H. Y. 2003. Conjugated linoleic acid inhibits cell proliferation and ErbB3 
signaling in HT-29 human colon cell line. American Journal of Physiology, 284, 
G996-G1005. 
ELLSWORTH, J. L., ERICKSON, S. K. & COOPER, A. D. 1986. Very low and low density 
lipoprotein synthesis and secretion by the human hepatoma cell line Hep-G2: effects 
of free fatty acid. Journal of lipid research, 27, 858-74. 
 
 
 
 
88 
 
HA, Y. L., GRIMM, N. K. & PARIZA, M. W. 1987. Anticarcinogens from fried ground 
beef: heat-altered derivatives of linoleic acid. Carcinogenesis, 8, 1881-1887. 
HANAHAN, D. & WEINBERG, R. A. 2011. Hallmarks of cancer: the next generation. Cell, 
144, 646-74. 
KEATING, A. F., ZHAO, F.-Q., FINUCANE, K. A., GLIMM, D. R. & KENNELLY, J. J. 
2008. Effect of conjugated linoleic acid on bovine mammary cell growth, apoptosis 
and stearoyl Co-A desaturase gene expression. Domestic Animal Endocrinology, 34, 
284-292. 
KELLEY, N. S., HUBBARD, N. E. & ERICKSON, K. L. 2007. Conjugated Linoleic Acid 
Isomers and Cancer. Journal of Nutrition, 137, 2599-2607. 
KEMP, M. Q., JEFFY, B. D. & ROMAGNOLO, D. F. 2003. Conjugated Linoleic Acid 
Inhibits Cell Proliferation through a p53-Dependent Mechanism: Effects on the 
Expression of G1-Restriction Points in Breast and Colon Cancer Cells. Journal of 
Nutrition, 133, 3670-3677. 
KENNEDY, A., MARTINEZ, K., SCHMIDT, S., MANDRUP, S., LAPOINT, K. & 
MCINTOSH, M. 2010. Antiobesity mechanisms of action of conjugated linoleic acid. 
J Nutr Biochem, 21, 171-9. 
KHANAL, R. C. 2004. Potential Health Benefits of Conjugated Linoleic Acid (CLA): A 
Review Asian-Aust. J. Anim. Sci., 17, 1315-1328. 
 
 
 
 
89 
 
KIM, E. J., KANG, I.-J., CHO, H. J., KIM, W. K., HA, Y.-L. & PARK, J. H. Y. 2003. 
Conjugated Linoleic Acid Downregulates Insulin-Like Growth Factor-I Receptor 
Levels in HT-29 Human Colon Cancer Cells. The Journal of Nutrition, 133, 2675-
2681. 
LI, T., KON, N., JIANG, L., TAN, M., LUDWIG, T., ZHAO, Y., BAER, R. & GU, W. 2012. 
Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and 
senescence. Cell, 149, 1269-83. 
LIM, D. Y., TYNER, A. L., PARK, J. B., LEE, J. Y., CHOI, Y. H. & PARK, J. H. 2005. 
Inhibition of colon cancer cell proliferation by the dietary compound conjugated 
linoleic acid is mediated by the CDK inhibitor p21CIP1/WAF1. J Cell Physiol, 205, 
107-13. 
MELAKU, A., KADIR, A. A., OTHMAN, F., MENG, G. Y. & SAZILI, A. Q. 2012. 
Cytotoxic effects of conjugated linoleic acids on human hepatoma cancer cells 
(HepG2). J Mol Pathophysiol, 1, 43-48. 
MINER, J. L., CEDERBERG, C. A., NIELSEN, M. K., CHEN, X. & BAILE, C. A. 2001. 
Conjugated linoleic acid (CLA), body fat, and apoptosis. Obes Res, 9, 129-34. 
MOLONEY, F., YEOW, T.-P., MULLEN, A., NOLAN, J. J. & ROCHE, H. M. 2004. 
Conjugated linoleic acid supplementation, insulin sensitivity, and lipoprotein 
metabolism in patients with type 2 diabetes mellitus. American journal of clinical 
nutrition, 80, 887-895. 
 
 
 
 
90 
 
MOONEY, D., MCCARTHY, C. & BELTON, O. 2012. Effects of conjugated linoleic acid 
isomers on monocyte, macrophage and foam cell phenotype in atherosclerosis. 
Prostaglandins and Other Lipid Mediators, 98, 56-62. 
NOTO, A., ZAHRADKA, P., YURKOVA, N., XIE, X., NITSCHMANN, E., OGBORN, M. 
& TAYLOR, C. G. 2006. Conjugated linoleic acid reduces hepatic steatosis, improves 
liver function, and favorably modifies lipid metabolism in obese insulin-resistant rats. 
Lipids, 41, 179-88. 
OCHOA, J. J., FARQUHARSON, A. J., GRANT, I., MOFFAT, L. E., HEYS, S. D. & 
WAHLE, K. W. J. 2004. Conjugated linoleic acids (CLAs) decrease prostate cancer 
cell proliferation: different molecular mechanisms for cis-9, trans-11 and trans-10, 
cis-12 isomers. Carcinogenesis, 25 1185-1191. 
SALAKOU, S., KARDAMAKIS, D., TSAMANDAS, A. C., ZOLOTA, V., 
APOSTOLAKIS, E., TZELEPI, V., PAPATHANASOPOULOS, P., BONIKOS, D. 
S., PAPAPETROPOULOS, T., PETSAS, T. & DOUGENIS, D. 2007. Increased 
Bax/Bcl-2 ratio up-regulates caspase-3 and increases apoptosis in the thymus of 
patients with myasthenia gravis. In Vivo, 21, 123-32. 
SRAVAN KUMAR, G. & DAS, U. N. 1997. Cytotoxic action of alpha-linolenic and 
eicosapentaenoic acids on myeloma cells in vitro. Prostaglandins Leukotrienes and 
Essential Fatty Acids, 56, 285-93. 
 
 
 
 
91 
 
WANG, J., LIU, X., ZHANG, X., LIU, J., YE, S., XIAO, S., CHEN, H. & WANG, H. 2013. 
Induction of apoptosis by c9, t11-CLA in human endometrial cancer RL 95-2 cells via 
ERalpha-mediated pathway. Chemistry and physics of lipids, 175-176C, 27-32. 
YUN, H. S., DO, S. H., JEONG, W. I., YANG, H. J., YUAN, D. W., HONG, I. H., LEE, H. 
R., LEE, I. S., KIM, Y. K., CHOI, M. S., KIM, H. A. & JEONG, K. S. 2008. 
Cytotoxic effects of the conjugated linoleic acid isomers t10c12, c9t11-CLA and 
mixed form on rat hepatic stellate cells and CCl4-induced hepatic fibrosis. J Nutr 
Biochem, 19, 175-83. 
 
 
 
 
 
92 
 
 
 
  
 
 
 
 
 
CHAPTER 5 
 
  
 
 
 
 
93 
 
THE EFFECT OF CIS9-TRANS11 AND TRANS10-CIS12 CONJUGATED LINOLEIC 
ACID ON THE LIPID PROFILE OF HEPG2 CELLS 
L.B. Arendse
1,2
, M. De Kock
2
, W.C.A. Gelderblom
1
, S. Abel
1
. 
1
Institute of Biomedical and Microbial Biotechnology (IBMB), Cape Peninsula University of 
Technology, PO box 1906, Bellville, 7535; 
2
Department of Medical Biosciences, University 
of the Western Cape, Private Bag x17; Bellville, 7535. 
5.1. Abstract 
Although the biological effects of conjugated linoleic acids (CLA) have been studied 
extensively, their mechanisms of action remain unclear. They have shown to reduce the 
growth and progression of cancer cells amongst other health benefits including anti-
atherogenic and anti-adipogenic activity. The aim of this study is to determine the effect of 
c9t11 CLA and t10c12 CLA isomers on the lipid profile of HepG2 cells and how they 
compare to linoleic acid (LA) and α-linolenic acid (ALA). Briefly, cells were supplemented 
with concentration of FA-BSA complexes for 48 hours. FA were extracted, separated into 
respective phospholipid fractions (PC and PE) and measured by gas chromatography. 
Cholesterol and phospholipid concentrations were also quantified by cholesterol enzymes and 
malachite green methods respectively. No significant effect was seen on cholesterol and 
phospholipid concentration in all treated samples. The c9t11 CLA isomer increased the 
concentration of all fatty acids in both the PC and PE phospholipid fractions. The t10c12 
CLA isomer significantly reduced the MUFA concentration in both PC and PE fractions. LA 
and ALA expectedly increased N6 and N3 FA concentrations, respectively. The results show 
that t10c12 CLA and c9t11 CLA have varying effects on HepG2 cancer cell membrane 
composition. This may partially explain their effect on cancer cell growth and development. 
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Altering the membrane FA composition results in modification of a number of downstream 
events including; prostaglandin production, inflammation and lipid peroxidation or cellular 
stress events. Future studies including cycle events and gene expression are required to fully 
uncover the anticancer effect of CLA. 
 
5.2. Introduction 
Conjugated linoleic acid (CLA) is a group name for the positional isomers of linoleic acid, 
which are characterized by conjugated double bonds. They are intermediate products in the 
biohydrogenation of unsaturated fatty acids (FA) by microorganisms in the rumen. CLA can 
also be produced endogenously in tissues, such as the mammary gland of ruminants (Adlof et 
al., 2000). Several positive physiological effects are reported for CLA, like anti-carcinogenic, 
anti-atherogenic and immuno-modulatory properties (Bhattacharya et al., 2006). 
Supplementations with FA can influence the function of immune cells and epithelial cells in 
the liver and colon through different mechanisms, i.e. change the FA profile of the cellular 
membrane and subsequently affecting signal transduction pathways and lipid mediators like 
prostaglandin E2 (Calder, 2013, Serhan and Chiang, 2002). For example CLA 
supplementation led to decreased lymphocyte activation of healthy men (Tricon et al., 2004) 
and declined proliferative response in rat splenocytes (Renner et al., 2012). The CLA isomers 
incorporation profiles in the cell membrane differ greatly from that of LA; this may well lead 
to membrane function alterations. Dietary FA intake has shown to alter the lipid profile of 
cellular membranes. Changing the lipid composition on the cell membrane ultimately 
modifies cellular functions (Gill and Clark, 1980). 
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Polyunsaturated fatty acids (PUFAs) can induce growth inhibition and cytotoxicity of tumour 
cells in vitro via mechanisms involving free radical generation (Das et al., 1987) resulting in  
lipid peroxidation (Hawkins et al., 1998) and cell cycle arrest (Palakurthi et al., 2000). CLA 
isomers showed comparable results to iron induced lipid peroxidation to LA, which was not 
as effective at protecting against lipid peroxidation as mono-unsaturated FA (MUFA). The 
CLA isomers also showed a marked effect on cell proliferation and apoptosis, by increasing 
apoptosis and decreasing cell proliferation in varying degrees.  
The purpose of this study was to determine the effect of the two main CLA isomers; cis9-
trans11 (c9t11) and trans10-cis12 (t10c12) CLA, as well as two essential fatty acids; linoleic 
acid (LA) and alpha-linolenic acid (ALA) on FA incorporation, phospholipids and cellular 
cholesterol. 
 
5.3. Materials and Methods 
5.3.1. Chemicals 
All FA’s were acquired from Sigma-Aldrich (South Africa): linoleic acid (Cat # 60333), 
conjugated linoleic acids c9t11 (Cat# 2540569), t10c12 (Cat# 2420566), α-linolenic acid (Cat 
# 463401), 99 % ethanol (Sigma-Aldrich Cat # 64175), Dulbecco’s phosphate buffered saline 
(DPBS; pH = 7.0 - 7.2, Cat# 14190250). Culture media: Eagle’s Minimum Essential Medium 
(Lonza Cat # BE12-125F) supplemented with 10 % fetal bovine serum (FBS), 1 % non-
essential amino acids, 1 % pyruvate and 1 % L-glutamate. Treatment media: Eagle’s 
Minimum Essential Medium supplemented with 5 % FBS, 1 % non-essential amino acids, 1 
% pyruvate and 1 % L-glutamate. Trypsin/EDTA (Lonza Cat # CC5012), Hanks' Balanced 
Salt Solution (HBSS) (Lonza Cat# 10-508F), phenolphthalein (Analar 37188), 0.1M NaOH, 
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Fatty acid free bovine serum albumin (BSA, Roche Cat # 70335128), chloroform, methanol, 
butylated hydroxytoluene (BHT), thin layer chromatography (TLC) solvent: 
chloroform:methanol:petroleum benzene:acetic acid:boric acid (40:20:30:10:1.8; v/v/v/v/w), 
2,5-bis-(5’-tert-butylbenz-oxazolyl-2’)thiophene (BBOT, CAS# 7128-64-5), saline, CMS 
(chlorophorm:methanol:saline, 86:14:1), Malachite green phosphate detection kit from R&D 
Systems (Cat # DY996), 6 N KOH, perchloric acid, BCA Protein Assay Reagent A (Pierce 
#23223), Reagent B (4 % CuSO4.5H2O), 0.1 mg BSA standard, glacial acetic acid, anhydrous 
sodium sulphate, Triton X-100, SDS solution (2% sodium dodecyl sulphate, 20 mM 
NaHCO3, 2 mM EDTA) 
 
5.3.2. Maintenance of HepG2 cell culture 
HepG2 cells (ATCC HB-8065) were cultured in 75 cm
3
 flasks with culture mediums 
described above and sub-cultured at 80% confluency. Culture medium was replaced when 
necessary.  
 
5.3.3. Preparation of fatty acids 
Stocks (10 mM) of the individual FAs (c9t11, t10c12, ALA, LA) were complexed with FA-
free BSA for treatment of cell cultures, according to a previously described method 
(Ellsworth et al., 1986). Briefly, the required FAs were measured relative to the amount 
needed to make up the final concentration and mixed with 1 ml pure ethanol and 1 mg 
phenolphthalein. A 0.1M NaOH solution was used to titrate the mixture and solvent was 
evaporated on a 37°C heating block under N2 gas. The FA salt was then dissolved in DPBS, 
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half the volume required to make the 10 mM solution. A BSA solution (5 mM) was prepared 
in DPBS and added to the respective FA salt solution in equal volume to make up a 10 mM 
FA stock solution required for treatment of the cells. 
 
5.3.4. Fatty acid treatment of HepG2 cells 
The respective 10 mM FA stock solutions prepared as described above, were diluted with 
treatment media containing 5% FBS (above) to the required concentrations ranging between 
0.01 mM and 0.8 mM. 
HepG2 cells were trypsinated, spun down and seeded at 4x10
6
 cells per 10 cm petri dish in 7 
ml culture medium and allowed to attach for 24 hours. Thereafter, the culture medium was 
removed and replaced with 8 ml treatment medium containing the FA-BSA solution prepared 
above. Cells were then incubated for 48 hours and collected for determining FA, 
phospholipid and cholesterol content. 
 
5.3.5. Lipid extraction 
After the 48 hour incubation period, cells from 3 petri dishes were scraped off, combined and 
lipids were extracted with chloroform/methanol (CM; 2:1; v/v) containing 0.01% BHT. 
Briefly, the method adapted from Folch et al. (1957): the HepG2 cells were resuspended in 
0.5 ml saline in a 40ml Teflon-capped glass tube and 0.1 ml was removed for protein 
determination. CM (12 ml) was added to the 0.4 ml resuspended cells and shaken for 20 
minutes. Saline saturated with CMS (4 ml) was added, mixed, centrifuged for 15 minutes and 
500 rpm and the lower chloroform-rich phase was transferred to a round bottom flask. The 
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cell suspension was re-extracted with 10 ml CMS, as above, and the bottom phase were 
combined with the previous in the round bottom flask. This procedure was repeated once 
more. The combined lower phases were evaporated on a rota-vapor and the dried lipid extract 
was washed over into a 12 ml Teflon-capped glass tube with 5 X 2 ml CMS. Thereafter, 1 ml 
saline saturated with CMS was added, the contents mixed, centrifuged at 500 rpm for 15 min 
and the top aqueous phase was removed. The CMS was evaporated under N2 gas in a 37°C 
water bath till dry, rinsed with 3 X 1 ml CMS while drying and then the tubes containing the 
dried lipid extract were placed on ice for phospholipid fractionation by TLC.  
 
5.3.6. Thin layer chromatography (TLC) 
The dried lipid extracts, from above, were dissolved in ice cold CMS (100ul) and 2x20 µl 
was removed for cholesterol determination in a separate glass tube. A further 60 µl was 
removed for phospholipid fractionation on silica TLC glass plates and applied on 2 separate 
10 x 20 mm silica TLC plates for FA (30 µl) and phospholipids (30 µl) analyses. The plates 
were developed using the TLC solvent (above) containing the fluorescent agent, for 90 
minutes. The plates were dried under N2 gas and BBOT solution was used to visualize the 
phospholipid fractions under a UV light. The lipid fractions phosphatidylcholine (PC) and 
phosphatidylethanolamine (PE) were identified against a phospholipid standard containing 
different phospholipid fractions. 
 
 
 
 
 
 
 
99 
 
5.3.7. Fatty acid analyses 
For FA analyses the phospholipid fractions, PC) and (PE, were scraped off the TLC plates 
into separate Teflon-capped glass tubes. For FAME preparation by base catalysis, it was 
necessary to first extract the phospholipids from the silica (Christie et al., 2007): 2 ml 
chlorophorm: methanol: water (C:M:W; 5:5:1) was added to the silica samples, mixed and 
centrifuged for 10 minutes at 1000 rpm . The supernatant was transferred to a clean Teflon-
caped glass tube. The silica was re-extracted with a further 2 ml CMW and the upper solvent 
phase was combined with the previous extract. The CMW was then evaporated under N2 gas 
in a 37°C water bath until dry. Thereafter, FAME were prepared from the dried extract as 
follows (Christie et al., 2007): 12 µg C17:0 (internal standard) was added together with 1 ml 
hexane and mixed to dissolve the dried extract. To this mixture, 40 µl sodium methoxide was 
added  and 40 µl methylacetate, the tube mixed, sealed with N2 gas and placed on a 50°C 
heating block for 15 minutes. Thereafter, glacial acetic acid (100 µl) was added to neutralize 
the methylation reaction as well as anhydrous sodium sulphate (1 mg). The solution was 
mixed and centrifuged at 100 rpm for 10 minutes. The upper solvent phase containing the 
FAME was transferred to a new Teflon-capped glass tube, evaporated under N2 gas and 
dissolved in10 µl hexane before injecting into a GC (Varian 3300 gas chromatograph) 
equipped with 30 m fused silica BPX-70 capillary columns (SGE, USA) of 0.32 mm internal 
diameter.  
 
5.3.8. Phospholipid determination 
The phospholipid fractions PC and PE were determined colorimetrically using the Malachite 
green phosphate detection kit from R&D Systems. Briefly, PC and PE fractions were 
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fractionated by TLC and collected into glass tubes as described above. The dry silica samples 
were digested in perchloric acid (i.e. PC: 400 µl; PE: 300 µl) on a 170°C heating block for 
two hours. After digestion, 6 N KOH (i.e. PC: 775 µl; PE: 581 µl) and distilled water was 
added to the samples at a ratio of 5: 1. Samples were mixed and centrifuged at 1000 rpm for 
15 minutes and 80 µl of the samples were transferred to 96 well microtitre plates in duplicate. 
The assay was carried out as per the manufacturers’ instructions and the colour development 
was measured spectrophotometrically at 620 nm and referenced against a phosphate standard 
curve. 
 
5.3.9. Cholesterol determination 
The cholesterol content of HepG2 cells was determined by an enzymatic iodide method using 
cholesterol-oxidase and cholesterol-esterase (Richmond, 1973). Briefly, 20 µl of the lipid 
extract was used per unknown sample; the solvent was removed under N2 gas in a 37°C water 
bath. The dried samples were dissolved in 20 µl CM (2:1) and placed on a 50°C heating 
block for 30 minutes. Thereafter, 50 µl Triton X-100 was added mixed and the sample tube 
centrifuged for 1 minute at 1000 rpm. A 20 µl aliquot was transferred to a 96 well microtitre 
plate, in duplicate. Cholesterol reagent B (20 µl) (Addendum 6) was added to sample 
solution, vortexed and left to incubate for 15 minutes. The absorbance was measured 
spectrophotometrically at 365 nm with samples being referenced against cholesterol blank. 
Cholesterol content was quantified against a cholesterol standard curve. 
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5.3.10. Protein determination 
The sample cellular protein concentration was determined by the Bicinchoninic Acid (BCA) 
protein assay (Kaushal and Barnes, 1986). Samples were diluted in SDS solution to denature 
proteins. A BSA standard was prepared ranging from 1 µg to 10 µg protein to construct a 
standard curve. Absorbance readings were determined spectrophotometrically at 562 nm and 
the unknown protein concentration determined from the standard curve (Addendum 2). 
 
5.3.11. Statistical analyses 
All experiments were carried out in quadruplicate and repeated for consistency. The 
statistical significance between groups was assessed by analysis of variance (ANOVA). An 
interaction effect was included to test for a difference in slope for the FA. A significant 
interaction effect would indicate that the different concentrations reacted differently for all 
the FA. Statistical significance was considered at 5% (P<0.05). 
 
5.4. Results 
5.4.2. Phospholipids  
The PC fraction (Table 5.1) phospholipid concentration (per mg protein) was not affected by 
c9t11 CLA, LA and t10c12 CLA, but was significantly lower (P<0.05) in ALA treated 
samples compared to untreated control.  
In PE (Table 5.2), the t10c12 CLA isomer showed a dose dependent phospholipid reduction 
(P<0.05) between highest and lowest concentration (0.5 and 0.075 mM respectively) 
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resulting in the highest concentration significantly lower (P<0.05) than the untreated control. 
PE concentration was significantly lower (P<0.05) in LA and ALA treated samples compared 
to control, while no significant effect was observed in c9t11 CLA treated samples although 
values tended to be lower than control. 
The PC/PE phospholipid ratio (Table 5.3) was not significantly affected by the treatments 
compared to controls, although the ratio tended to be lower in the ALA-treated group. 
 
5.4.3. Cholesterol  
Cholesterol was n not significantly affected for all tested FA at all concentrations (data not 
shown). 
 
5.4.4. Fatty acids 
Treatment FAs, c9t11, t10c12, LA and ALA were incorporated into the cell membrane (PC 
and PE fractions) in a dose dependent manner (P<0.05) compared to untreated control, while 
t10c12 was incorporated (P<0.05) but did not show a dose response.   
 
5.4.4. Phosphotidylcholine (PC) (Table 5.1)   
5.4.4.1. Saturated fatty acids (SATS; C14:0, C16:0, C18:0 and C22:0) 
t10c12 CLA: Compared to control, t10c12 CLA treatment did not significantly affect the 
Total SATS, although the lower concentration (0.75mM) resulted in a significantly higher 
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level of C16:0 and c18:0 as well as with a dose of 0.15mM for C18:0. Overall, t10c12 tended 
to increase the SATS at the lower dose resulting in a decrease in FA levels with increase in 
dose to control levels. However within the treatments, there was a significant (P<0.05) 
interaction resulting in a significant (P<0.05) dose difference (decrease) between 0.075 mM 
and 0.5 mM in Total SATS, was also reflected in C16:0 and C18:0 (P<0.05). C14:0 tended to 
show a decrease as t10c12 increased dose wise. 
LA: Compared to control, LA significantly increased the Total SATS (P<0.05) at 0.15 mM 
which drops significantly (P<0.05) at 0.3 and 0.6 mM, also reflected by C16:0 and C18:0. 
Within treatments, C14:0, C16:0 and C18:0 were significantly (P<0.05) dose-dependently 
decreased. 
c9t11 CLA: Treatment with c9t11 significantly (P<0.05) increased the Total SATS compared 
to the control, also reflected by increases (P<0.05) in the individual SATS FAs in a c9t11 
dose-dependent manner.  
ALA: Treatment with ALA did not affect any SATS parameters compared to control or 
between concentrations. 
 
5.4.4.2. Monounsaturated fatty acids (C16:1, C18:1n9, C18:1n7 and C20:1n9) 
t10c12 CLA: Compared to control, t10c12 CLA significantly (P<0.05) lowered Total 
MUFA, reflected by decreases in C16:1n-7, C18:1n-9 and C18:1n-7 (P<0.05). Within the 
treatments, a significant (P<0.05) interaction resulting in a dose dependent decrease in Total 
MUFA, also reflected in C18:1n9 (P<0.05). 
 
 
 
 
104 
 
LA: Total MUFA was significantly (P<0.05) lowered by LA compared to control in a dose-
dependent manner (P<0.05), reflected by reduction in C16:1, C18:1n-9 and C18:1n-7 
(P<0.05). The lower dose of 0.15 mM had a lesser effect on MUFA content than 0.3 and 0.6 
mM 
c9t11 CLA: Compared to control, C9T11 CLA significantly increased (P<0.05) Total 
MUFA, also reflected by increases (P<0.05) in the individual MUFAs. Within the treatments, 
only C20:1n-9 increased dose-dependently (P<0.05) from the 0.05 mM to 0.1 mM dose. 
ALA: Compared to control, ALA significantly (P<0.05) lowered Total MUFA, reflected by 
significantly (P<0.05) reduced individual MUFAs, except for C20:1n-9. Between the doses 
there was a downward trend as ALA concentration increased, although the change was not 
statistically significant. 
 
5.4.4.3. N6 PUFA (C18:2, C18:3, C20:2, C20:3, C20:4 and C22:5) 
t10c12 CLA: Compared to control, t10c12 CLA did not significantly affect Total N6 PUFA, 
although a significantly (P<0.05) lower C20:3n-6 and dose-dependent reduction in C20:4 
(P<0.05) was observed.  
LA: Compared to control, LA significantly (P<0.05) increased Total N6 PUFAs in a dose-
dependent manner (P<0.05), reflected in all identified N6 PUFAs.  
c9t11 CLA: Compared to control, C9T11 CLA significantly (P<0.05) increased Total N6 
PUFAs dose-dependently (P<0.05), reflected by dose-dependent (P<0.05) increase of 
C18:2n-6 and C20:4n-6.  
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ALA: Treatment with ALA increased Total N6 PUFAs slightly compared to the control, 
which was attributed to a significant increase in C18:2n-6 as well as a dose-dependent 
(P<0.05) increase in C18:2n-6. 
 
5.4.4.4. N3 PUFA (C18:3, C20:3, C20:5, C22:5 and C22:6) 
t10c12 CLA: Compared to control, t10c12 significantly lowered (P<0.05) Total N3 PUFA, a 
dose-dependent (P<0.05) between highest and lowest concentration, 0.5 and 0.075 mM 
respectively) decrease in Total N3 PUFA was observed, as reflected in C22:6.  
LA: Treatment with LA significantly (P<0.05) increased Total N3 PUFA compared to 
control, reflected by significant (P<0.05) increase in C22:5 and C22:6, although at higher 
doses LA lowered (P<0.05) the level within the treatment groups.  
c9t11 CLA: The c9t11 CLA isomer significantly (P<0.05) increased Total N3 PUFA 
compared to control which was reflected by significant (P<0.05) increases in C22:5, C22:6 
and C20:5.  
ALA: Compared to control, ALA significantly (P<0.05) increased Total N3 PUFA in a dose-
dependent (P<0.05) manner, reflected by significant increases in C20:5, C22:5 and dose-
dependent increase in C18:3 and C20:3. ALA also showed a dose-dependent (P<0.05) 
reduction in C22:6 that was not significant when compared to the controls. 
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5.4.4.5. PUFA and LCPUFA 
t10c12 CLA: Treatment with t10c12 demonstrated no effect on PUFA compared to control, 
while LCPUFA was significantly (P<0.05) lower at the highest dose. Within treatments, there 
appeared to be a dose dependent decrease.  
LA: Treatment with LA resulted in a significant increase (P<0.05) for both PUFA and 
LCPUFA compared to control. However within treatments, PUFA significantly (P<0.05) 
increased as per dose but the LCPUFA decreased (P<0.05).  
c9t11 CLA: The c9t11 CLA isomer significantly increased (P<0.05) PUFA and LCPUFA, 
although only the PUFA responded dose dependently (P<0.05).  
ALA: This same pattern was elicited by ALA treatment. 
 
5.4.5. Phosphotidylethanolamine (PE) Table 5.2 
5.4.5.1. Saturated fatty acids (C14:0, 16:0 and 18:0) 
t10c12 CLA: Compared to control, t10c12 CLA treatment did not significantly affect the 
Total SATS. However within the treatments, the Total SATS demonstrated a tendency to 
decrease dose dependent while there was a significant (P<0.05) decrease in C18:0 between 
0.075 mM and 0.5 mM.  
LA: Compared to control, LA significantly (P<0.05) increased Total SATS, reflected by 
significant (P<0.05) increase in all individual identified SATS. Within the treatments, C14:0 
increased (P<0.05) dose dependent in contrast to a dose-dependent decrease (P<0.05)  C18:0. 
c9t11 CLA: Treatment with c9t11 CLA significant (P<0.05) increased Total SATS compared 
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to control in a dose dependent (P<0.05) manner, which was reflected by significant (P<0.05) 
dose-dependent increase in the entire individual identified SATS.  
ALA: Compared to control, ALA did not affect Total SATS significantly. No dose dependent 
treatment effects were observed. 
 
5.4.5.2. Monounsaturated fatty acids (C16:1, C18:1n-9, C18:1n-7 and C20:1n-9) 
t10c12 CLA: Compared to control, t10c12 CLA significant (P<0.05) reduced the Total 
MUFA in a dose dependent manner (P<0.05).  
LA: Treatment with LA showed a significant (P<0.05) dose-dependent increase in Total 
MUFA at the lowest dose compared to the control, which was reflected by C18:1n-7 and 
C20:1n-9. However, this increase was negated by a tendency to decrease dose dependently 
with LA treatment, particularly with C16:1n-7 and C18:1n-9 (P<0.05). Overall, an increase in 
Total MUFA is evident, which decreases as the LA concentration increases. 
c9t11 CLA: The c9t11 CLA isomer significantly increased Total MUFA (P<0.05) compared 
to control, reflected by significant (P<0.05) increases of all individual identified MUFAs, 
with C20:1n-9 increasing dose dependently (P<0.05).  
ALA: Treatment with ALA significantly (P<0.05) reduced Total MUFA compared to 
control, that is reflected by reduction of all identified MUFAs at 0.3 mM ALA concentration. 
 
 
 
 
 
 
108 
 
5.4.5.3. N6 PUFA (C18:2, C18:3, C20:2, C20:3, C20:4, C22:4 and C22:5) 
t10c12 CLA: The t10c12 CLA isomer appeared to significantly decrease (P<0.05) the Total 
N6 PUFA, only significant (P<0.05) at the lowest dose, reflected by significant (P<0.05) 
reduction of all identified N6 PUFA.  
LA: Compared to control, LA significantly increased Total N6 PUFA (P<0.05) as well as in 
a dose-dependent (P<0.05) manner, reflected by significant dose-dependent increases 
(P<0.05) in C18:2, C18:3, C20:2, C22:4. However, C20:3, C20:4 and C22:5 decreased 
(P<0.05) dose dependently.  
c9t11 CLA: The c9t11 CLA isomer significantly increased Total N6 PUFA (P<0.05), 
reflected by significant increase in C20:4, C18:2 and C20:3.  
ALA: Compared to control, ALA did not affect the Total N6 significantly, however ALA 
significantly (P<0.05) increased C18:2, but decreased C20:4.  
 
5.4.5.4. N3 PUFA (C18:3, C20:3, C20:5, C22:5 and C22:6) 
t10c12 CLA: Compared to control, t10c12 CLA significantly (P<0.05) decreased Total N3 
PUFA, reflected by significant decrease in C20:5 and C22:6.  
LA: Treatment with LA did not significantly affect Total N3 PUFA, however a dose 
reduction is evident, reflected in the significant (P<0.05) dose reduction in C22:6.  
c9t11 CLA: Compared to control, c9t11 CLA significantly (P<0.05) increased Total N3 
PUFA, reflected by significant (P<0.05) increase in C22:6 and dose-dependent (P<0.05) 
increase in C20:5.  
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ALA: Treatment with ALA significantly (P<0.05) increased Total N3 PUFA in a dose-
dependent (P<0.05) manner compared to control, reflected by significant (P<0.05) dose 
dependent increases in C18:3 and C20:3. 
 
5.4.5.5. PUFA and LCPUFA 
Overall, t10c12 significantly (P<0.05) lowered PUFA and LCPUFA levels, whereas c9t11 
significantly (P<0.05) increased these two parameters. These two parameters were similarly 
increased (P<0.05) by LA and ALA. 
 
5.4.6. FA ratios Table 5.3 
5.4.6.1. N6/N3  
(PC) c9t11 and ALA significantly decreased (P<0.05) the N6/N3 fatty acid ratio, but the 
effect of ALA was greater as the concentration increase and the effect of c9t11was inversely 
proportional.  LA Significantly increased (P<0.05) the N6/N3 fatty acid ratio in a dose 
dependent manner (P<0.05), while T10C12 was not significant. 
 (PE) c9t11 CLA and ALA significantly decrease (P<0.05) the N6/N3 fatty acid ratio, but the 
effect of ALA was greater as the concentration increase whereas the effect of c9t11 was 
inversely proportional.  LA Significantly increased the N6/N3 fatty acid ratio in a dose 
dependent manner (P<0.05), while t10c12 was not significant, but did show significant dose 
increase (P<0.05) in the ratio. 
 
 
 
 
 
110 
 
5.4.6.2. P/S  
(PC) The P/S ratio was significantly increased by all fatty acids (P<0.05) except t10c12, 
which did not alter the ratio at all. 
(PE) The P/S ratio was significantly increased (P<0.05) by LA and ALA, decreased by c9t11 
CLA, and unaffected by t10c12 CLA, which did not alter the ratio at all. 
 
5.4.6.3. AA/EPA ratio (arachidonic acid/eisocapentanoic acid, C20:4n6/C20:5n3). 
(PC) Compared to control, c9t11CLA and ALA significantly increased (P<0.05) the 
AA/EPA as a result of increasing EPA to within a detectable level. 
(PE) Compared to control, t10c12 CLA significantly increased (P<0.05) the AA/EPA ratio at 
0.15 and 0.5 mM, with a significant difference (P<0.05) seen between 0.075 and 0.5 mM 
concentrations. In contrast, c9t11 CLA and ALA significantly reduced (P<0.05) the AA/EPA 
ratio. 
 
5.4.6.4. Desaturation indices (C16:1n-7/C16:0, C18:1n9/C18:0 and C18:1n7/C16:0) 
(PC) All FA at all concentrations significantly decreased (P<0.05) the desaturation index 
within the PC phospholipid fraction. 
(PE) The t10c12 CLA isomer and LA significantly decreased (P<0.05) the desaturation 
index, whereas c9t11 and ALA had no significant effect on the desaturation index of the PE 
phospholipid fraction. 
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5.4.6.4 Delta 6 desaturase substrate and product (Delta 6-S and Delta 6-P)  
5.4.6.4.1. PC 
t10c12 CLA: Compared to the control, t10c12 CLA treatment significantly increased Delta 6 
desaturase substrate and product at 0.5 mM. Concentration differences were seen where 0.05 
mM showed a significantly higher (P<0.05) effect than 0.075 and 0.15 mM.  
LA: Treatment with LA significantly increased (P<0.05) Delta 6 S/P ratio. A significant 
(<0.05) dose increase was seen between the highest concentration and the lowest 
concentration. 
c9t11 CLA: Delta 6 substrate was significantly increased by c9t11 CLA treatment, with dose 
difference between  0.2 mM and the two lower concentrations. Compared to control, Delta 6 
product showed similar increase, which resulted in an insignificant response in the Delta 6 
S/P ratio. 
ALA: Compared to control, ALA treatment significantly increased the Delta 6 substrate, with 
dose differences seen between 0.3 mM and the two lower concentrations. Slight reduction in 
Delta 6 product can be seen, which is dose significant (P<0.05). This effect significantly 
increased (P<0.05) the Delta S/P ratio in a dose dependent manner (P<0.05). 
 
5.4.6.4.2. PE 
t10c12 CLA: Compared to the control, t10c12 CLA treatment significantly decreased delta 6 
desaturase substrate at 0.075 and 0.15 mM. The Delta 6 S/P ratio was significantly increased 
(P<0.05) at 0.5 mM. 
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LA: Treatment with LA significantly increased (P<0.05) Delta 6 S in a dose dependent 
manner (P<0.05). Delta 6 P was also significantly increased, but dose difference seen 
between the higher concentrations and the lowest concentration. The Delta 6 S/P was not 
significantly affected. 
c9t11 CLA: Delta 6 substrate was significantly increased (P<0.05) by c9t11 CLA treatment, 
and a slight increase in Delta 6 P is evident, therefore the effect on the ratio did not differ 
significantly from the control. 
ALA: Treatment with ALA significantly increased (P<0.05) Delta 6 S. A dose increase was 
notable between 0.3 mM and the two lower concentrations. No effect on Delta 6 P was seen, 
therefore the Delta 6 S/P ratio elevated significantly (P<0.05) in a dose dependent manner 
(P<0.05).  
 
5.4.6.5. AA PC/PE (arachidonic acid PC/PE ratio) 
Treatment with t10c12 CLA was significantly higher than the control at 0.075 mM, which 
decreased as the concentration increased. LA, c9t11 CLA and ALA significantly increased 
(P<0.05) the AA PC/PE ratio compared to control, but no do differences between FA 
concentrations were seen.  
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Table 5.1: Fatty acid analysis (µg fatty acid/mg protein) of the phosphotidylcholine (PC) phospholipid fraction in HepG2 cells 
 t10c12 CLA LA c9t11 CLA ALA Control 
Dose (mM) 0.5 0.15 0.075 0.6 0.3 0.15 0.2 0.1 0.05 0.3 0.15 0.075 0 
SATS              
   C14:0 0.25±0.11 0.39±0.26 0.60±0.23 0.44±0.05b 0.37±0.07b 1.14±0.12*a 1.47±0.34*b 0.94±0.26 0.63±0.30a 0.40±0.16 0.43±0.18 0.37±0.13 0.45±0.15 
   C16:0 3.81±1.12b 5.31±0.66b 7.46±0.86*a 7.40±0.97*b 5.79±0.43b 11.4±1.48*a 19.5±3.26*c 15.4±2.14*b 11.3±0.75*a 5.10±1.31 5.24±1.72 4.97±0.35 4.53±0.99 
   C18:0 0.80±0.14b 1.48±0.18*a 1.55±0.59*a 0.91±0.12*b 1.01±0.37*b 1.62±0.07a 2.71±0.14*c 2.14±0.17*b 1.61±0.18*a 0.39±0.09 0.40±0.14 0.45±0.12 0.46±0.19 
Total SATS 4.57±1.51b 7.18±0.74 9.80±1.39a 8.75±1.13c 7.17±0.79b 14.2±1.578a 24.6±5.12*c 18.5±2.52*b 13.5±0.92*a 6.18±1.60 6.36±2.08 6.02 ±0.55 6.73±2.71 
              
MUFA              
   C16:1n-7 0.15±0.05* 0.41±0.11* 0.56±0.37* 0.44±0.04*b 0.45±0.03*b 1.22±0.15a 4.25±0.69* 4.37±0.68* 3.24±0.52* 0.55±0.15* 0.73±0.24* 0.87±0.11* 1.73±0.54 
   C18:1n-9 0.81±0.18*b 1.66±0.14* 2.78±1.02*a 0.91±0.11*b 1.07±0.21*b 2.44±0.12*a 7.66±1.33* 8.94±0.08* 8.03±0.86* 0.84±0.21* 1.19±0.35* 1.64±0.09* 3.29±0.36 
   C18:1n-7 0.46±0.12* 0.81±0.08* 1.32±0.64* 0.70±0.09*b 0.87±0.09*b 2.27±0.30a 3.76±0.46*b 4.92±0.13*a 4.60±0.58* 0.63±0.15* 0.84±0.26* 1.16±0.10* 2.34±0.57 
   C20:1n-9 0.33±0.12* 0.20±0.03 0.19±0.07 0.07±0.00*b 0.10±0.02b 0.22±0.04a 1.33±0.07*b 1.11±0.22*b 0.82±0.10*a 0.08±0.03 0.08±0.03 0.08±0.02 0.18±0.08 
Total MUFA 1.69±0.45* 3.08±0.22* 4.85±1.71* 2.15±0.20*b 2.48±0.32* 6.15±0.55a 17.0±2.38* 18.4±2.73* 16.7±1.43* 2.10±0.54* 2.84±0.86* 3.76±0.27* 8.42±2.76 
              
N6 PUFA              
   C18:2 0.45±0.14 0.57±0.03 0.57±0.19 8.86±0.58*c 6.54±0.73*b 4.98±0.64*a 2.95±0.52*b 2.27±0.17*a 1.85±0.23*a 1.67±0.15*c 1.39±0.64*b 0.88±0.17*a 0.60±0.22 
   C18:3 ND ND ND 2.24±0.17*c 2.71±0.34*b 0.10±0.01a ND ND ND ND ND ND ND 
   C20:2 ND ND ND 0.67±0.09*b 0.39±0.04*b 0.45±0.04*a ND ND ND ND ND ND 0.21±0.00 
   C20:3 0.01±0.01* 0.04±0.03 0.04±0.04 0.34±0.04*b 0.36±0.08*b 0.80±0.10*a 0.20±0.04* 0.22±0.03* 0.21±0.04* 0.04±0.01* 0.05±0.01* 0.06±0.00 0.09±0.03 
   C20:4 0.13±0.03b 0.24±0.04a 0.33±0.04*a 1.51±0.15*b 1.46±0.13*b 2.95±0.45*a 0.92±0.10*b 0.80±0.11 0.68±0.09a 0.15±0.03 0.14±0.04 0.16±0.01 0.17±0.07 
   C22:5 ND ND ND 0.06±0.01*b 0.07±0.01*b 0.16±0.02*a ND ND ND ND ND ND ND 
Total N6 0.73±0.26 0.85±0.05 0.94±0.15 13.6±0.77*c 11.5±0.81*b 9.62±1.09*a 4.07±0.52b 3.29±0.31*a 2.74±0.35*a 1.86±0.68 1.29±0.82 1.30±0.45 0.92±0.35 
              
N3 PUFA              
   C18:3 ND ND ND ND ND ND ND ND ND 3.79±0.88*c 1.83±0.57*b 0.85±0.11*a ND 
   C20:3 ND ND ND ND ND ND ND ND ND 0.58±0.12*b 0.40±0.13*a 0.27±0.03*a ND 
   C20:5 ND ND ND ND ND ND 0.55±0.09* 0.51±0.10* 0.43±0.04* 0.81±0.17* 0.80±0.24* 0.77±0.11* ND 
   C22:5 ND ND ND 0.03±0.01*a 0.02±0.00*b 0.03±0.00*a 0.04±0.00* 0.04±0.01* 0.04±0.00* 0.06±0.02* 0.06±0.02* 0.07±0.01* ND 
   C22:6 0.03±0.03*b 0.11±0.02 0.14±0.03a 0.25±0.05*b 0.18±0.02*b 0.39±0.03*a 0.50±0.06* 0.51±0.05* 0.48±0.08* 0.09±0.02b 0.11±0.03 0.18±0.03a 0.14±0.06 
Total N3 0.03±0.03*b 0.11±0.02 0.14±0.03a 0.28±0.06*b 0.20±0.02b 0.42±0.03*a 1.09±0.15* 1.06±0.15* 0.95±0.11* 5.32±1.20*b 3.21±0.98*a 2.14±0.28*a 0.15±0.07 
              
PUFA 0.79±0.33 0.96±0.07 1.13±0.13 13.9±0.77*c 11.7±0.82*b 10.0±1.11*a 5.17±0.65*b 4.35±0.45* 3.69±0.47*a 7.18±1.88*c 4.50±1.48*b 3.44±0.48*a 1.07±0.37 
LC PUFA 0.16±0.06*b 0.39±0.04a 0.56±0.13a 2.84±0.06*b 2.47±0.26*b 4.96±0.71*a 2.21±0.15* 2.08±0.29* 1.84±0.23* 1.72±0.36* 1.57±0.46* 1.50±0.18* 0.46±0.11 
LC /PUFA 0.18±0.03*b 0.40±0.08a 0.49±0.07a 2.84±0.06*b 2.47±0.26*b 4.96±0.71*a 2.21±0.15* 2.08±0.29* 1.84±0.23* 1.72 ± 0.36* 1.57±0.46* 1.50±0.18* 0.46±0.11 
              
CLA              
c9t11  0.65±0.10*c 0.46±0.07*b 0.22±0.90*a ND ND ND 11.1±0.32*c 5.89±1.06*b 2.77±0.24*a ND ND ND ND 
t10c12 4.85±0.77*c 3.76±0.57*b 2.60±0.29*a ND ND ND ND ND ND ND ND ND ND 
              
Phospholipids 46.12±12.41 73.02±25.03 69.65±27.00 43.14±6.92 46.45±5.11 42.15±4.42 64.57±3.87 55.97±5.72 61.99±3.03 30.33±3.03* 32.12±2.94* 25.28±2.85* 65.32±23.98 
Values are expressed as mean (µg fatty acid/mg protein) ± SD of 4 replications. * denotes significant (P<0.05) difference compared to control. The letters (a,b and c) denote a significant (P<0.05) difference between treatment according to ANOVA 
(analysis of variance) analyses, where a, b and c are all different. FA = fatty acid, mM = treatment concentration in mM, SATS = saturated fatty acids, MUFA = monounsaturated fatty acids, N6 PUFA = omega 6 polyunsaturated fatty acids, N3 
PUFA = omega 3 polyunsaturated fatty acids, PUFA = polyunsaturated fatty acids, FA containing 2 or more double bonds, LCPUFA = long chain polyunsaturated fatty acids gre ater than 20 carbons in length, LC/PUFA = the ration between long 
chain FA and  PUFA, CLA = conjugated linoleic acid, C9T11 = cis9-trans11 CLA, T10C12 = trans10-cis12 CLA, ND = not detected. 
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Table 5.2: Fatty acid analysis (µg fatty acid/mg protein) of the phosphotidylethanolamine (PE) phospholipid fraction in HepG2 cells 
Values are expressed as mean (µg fatty acid/mg protein) ± SD of 4 replications. * denotes significant (P<0.05) difference compared to control. The letters (a,b and c) denote a significant (P<0.05) difference between treatment according to ANOVA 
(analysis of variance) analyses, where a, b and c are all different. FA = fatty acid, mM = treatment concentration in mM, SATS = saturated fatty acids, MUFA = monounsaturated fatty acids, N6 PUFA = omega 6 polyunsaturated fatty acids, N3 
PUFA = omega 3 polyunsaturated fatty acids, PUFA = polyunsaturated fatty acids, FA containing 2 or more double bonds, LCPUFA = long chain polyunsaturated fatty acids gre ater than 20 carbons in length, LC/PUFA = the ration between long 
chain FA and  PUFA, CLA = conjugated linoleic acid, C9T11 = cis9-trans11 CLA, T10C12 = trans10-cis12 CLA, ND = not detected. 
FA t10c12 CLA LA c9t11 CLA ALA Control 
Dose (mM) 0.5 0.15 0.075 0.6 0.3 0.15 0.2 0.1 0.05 0.3 0.15 0.075 0 
SATS              
   C14:0 0.06±0.03 0.04±0.01 0.05±0.02 0.13±0.02*b 0.11±0.02* 0.08±0.01a 0.16±0.03*b 0.10±0.02a 0.07±0.02a 0.03±0.03 0.06±0.03 0.05±0.01 0.06±0.03 
   C16:0 0.90±0.17 1.00±0.09 1.63±0.71 2.24±0.41* 1.62±0.09b 2.51±0.54*a 3.10±0.47*b 2.78±0.28*b 1.88±0.21*a 0.98±0.39 1.13±0.26 1.02±0.05 1.11±0.37 
   C18:0 0.84±0.17b 1.23±0.07 1.40±0.16a 2.16±0.32*b 2.08±0.31*b 3.08±0.34*a 2.97±0.48*b 2.87±0.12* 2.21±0.38*a 1.35±0.25 1.29±0.30 1.03±0.03 1.06±0.32 
Total SATS 1.81±0.35 2.28±0.17 4.04±1.67 4.53±0.22* 3.81±0.38*b 5.68±0.77*a 6.24±0.93*b 5.76±0.41*b 4.16±0.29*a 2.36±0.66 2.53±0.59 2.11±0.04 2.11±0.04 
              
MUFA              
   C16:1n-7 0.11±0.04*b 0.19±0.03* 0.39±0.18*a 0.24±0.02*b 0.23±0.02*b 0.45±0.06a 1.37±0.22* 1.32±0.13* 1.16±0.21* 0.17±0.08* 0.27±0.07 0.28±0.02 0.43±0.13 
   C18:1n-9 0.98±0.21* 1.41±0.11 1.72±0.04 1.34±0.18*b 1.73±0.15b 3.02±0.28a 5.33±0.71* 5.70±0.24*b 4.33±0.45*a 1.09±0.25* 1.38±0.33 1.39±0.09 2.27±0.76 
   C18:1n-7 0.18±0.08* 0.28±0.02* 0.58±0.22* 0.78±0.12b 0.91±0.09b 2.37±0.91*a 1.65±0.23 1.97±0.04* 1.70±0.24* 0.55±0.11* 0.65±0.17 0.66±0.02 1.15±0.40 
   C20:1n-9 0.17±0.02 0.11±0.01 0.18±0.04 0.08±0.01b 0.12±0.02b 0.28±0.06*a 1.16±0.15*b 0.88±0.08*a 0.69±0.10*a 0.09±0.04 0.10±0.02 0.09±0.02 0.13±0.05 
Total MUFA 1.40±0.43* 2.00±0.13* 2.84±0.41 2.43±0.31b 2.99±0.23b 6.13±1.17*a 9.51±1.27* 9.77±0.57* 7.87±0.90* 1.90±0.48 2.39±0.57 2.43±0.10 3.98±1.29 
              
N6 PUFA              
   C18:2 0.24±0.18 0.17±0.01 0.23±0.06 5.95±0.36*c 3.59±0.97*b 2.00±0.56*a 1.52±0.21*b 1.03±0.31*a 1.06±0.25* 1.85±0.65* 1.38±0.62* 1.47±0.44* 0.26±0.09 
   C18:3 ND ND ND 2.54±0.39*b 2.85±0.17*b 0.04±0.01*a ND ND ND ND ND ND ND 
   C20:2 ND ND ND 0.75±0.15*b 0.36±0.03*a 0.33±0.05*a ND ND ND ND ND ND ND 
   C20:3 0.02±0.02b 0.05±0.01 0.06±0.03a 0.36±0.07*b 0.31±0.03*b 0.53±0.05*a 0.52±0.17*b 0.21±0.01a 0.18±0.03a 0.05±0.01 0.05±0.01 0.05±0.00 0.10±0.05 
   C20:4 0.53±0.15 0.70±0.06 0.54±0.2 2.03±0.46*b 2.42±0.20*b 4.48±0.36*a 1.42±0.23* 1.62±0.03* 1.23±0.25* 0.42±0.07* 0.44±0.10* 0.43±0.02* 0.76±0.21 
   C22:4 ND ND ND 0.28±0.07*b 0.20±0.02*a 0.20±0.03*a ND ND ND ND ND ND ND 
   C22:5 ND ND ND 0.32±0.09*b 0.40±0.05*b 0.67±0.08*a ND ND ND ND ND ND ND 
Total N6 0.83±0.56 0.91±0.27 0.83±0.14* 12.2±1.23*b 10.1±1.23*a 8.28±0.79*a 3.46±0.56* 2.86±0.29* 2.48±0.52 2.32±0.74 1.87±0.64 2.01±0.37 1.70±0.65 
              
N3 PUFA              
   C18:3 ND ND ND ND ND ND ND ND ND 2.32±0.53*c 1.03±0.23*b 0.47±0.09*a ND 
   C20:3 ND ND ND ND ND ND ND ND ND 0.49±0.08*c 0.25±0.06*b 0.12±0.01*a ND 
   C20:5 0.10±0.02 0.04±0.01* 0.03±0.02* ND ND ND 0.65±0.04*b 0.59±0.03*b 0.39±0.09*a 0.98±0.19* 1.09±0.26* 0.99±0.07* 0.09±0.05 
   C22:5 ND ND ND 0.08±0.02 0.09±0.01 0.11±0.02 0.13±0.02 0.15±0.00*b 0.11±0.01a 0.25±0.05* 0.23±0.06* 0.17±0.01 0.11±0.02 
   C22:6 0.14±0.06* 0.23±0.03* 0.21±0.08* 0.54±0.05*b 0.61±0.04*b 0.88±0.09*a 0.87±0.10 1.02±0.07*b 0.79±0.05a 0.42±0.08* 0.49±0.13* 0.56±0.04 0.70±0.08 
Total N3 0.13±0.08* 0.27±0.03* 0.26±0.07* 0.62±0.07 0.70±0.04 0.99±0.11 1.80±0.42* 1.76±0.09* 1.39±0.30 4.47±0.93*b 3.09±0.73*a 2.31±0.16*a 0.85±0.42 
              
PUFA 0.96±0.64* 1.19±0.10* 1.09±0.20* 12.8±1.29*b 10.7±1.26*a 9.26±0.87*a 5.27±0.87* 4.62±0.29* 3.87±0.83 6.76 ±1.67*b 4.96±1.11* 4.26±0.59a 2.72±0.68 
LC PUFA 0.57±0.32* 1.02±0.09* 0.86±0.25* 4.37±0.90*b 4.30±0.37*b 7.22±0.62*a 3.74±0.74* 3.59±0.11* 2.80±0.58* 2.62±0.49* 2.55±0.62 2.31±0.13 1.76±0.44 
LC /PUFA 0.18±0.03*b 0.18±0.03*b 0.40±0.08a 0.49±0.07a 2.84±0.16 2.47±0.24 4.96±0.22*b 2.21±0.13a 2.08±0.07a 1.84±0.52 1.72±0.49 1.57±0.46 1.50±0.18  
              
CLA              
c9t11 0.43±0.10*b 0.28±0.03* 0.26±0.13*a ND ND ND 9.98±0.99*c 4.89±0.40*b 2.02±0.31*a ND ND ND ND 
t10c12 1.76±0.56* 1.26±0.15* 1.25±0.64* ND ND ND ND ND ND ND ND ND ND 
              
Phospholipids 22.16±7.42*b 36.63±8.0.3 43.08±12.13a 29.70±4.15* 21.82±4.64* 28.11±3.30* 38.62±12.93 33.23±7.93 33.22±8.48 23.12±5.45* 28.76±7.71* 23.27±2.04* 43.03±7.46 
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Table 5.3: Fatty acid ratios (µg fatty acid/mg protein) of the PC and PE phospholipid fractions in HepG2 cells following treatment for 48 hours 
FA t10c12 CLA  LA  c9t11 CLA  ALA  Control 
Dose (mM) 0.5 0.15 0.075 0.6 0.3 0.15 0.2 0.1 0.05 0.3 0.15 0.075 0 
              
Phospholipid 
ratio PC/PE 
2.22±0.65 1.96±0.29 1.75±0.99 1.48±0.35 1.98±0.40 1.51±0.19 1.85±0.58 1.98±0.80 1.69±0.38 1.34±0.18 1.15±0.18 1.09±0.07 1.63±0.41 
              
PC FA ratios              
N6/N3 13.3±6.85*b 7.90±1.08 5.90±2.88a 51.5±12.3*b 58.7±6.01*b 22.8±1.97*a 3.74±0.31*b 3.13±0.24* 2.89±0.06*a 0.34±0.05* 0.42±0.30* 0.62±0.22* 5.76±0.45 
P/S 0.15±0.03 0.13±0.01 0.15±0.05 1.61±0.20*b 1.65±0.13*b 0.71±0.05*a 0.21±0.02 0.24±0.01* 0.27±0.04* 1.16±0.04*b 0.72±0.15*a 0.57±0.07*a 0.15±0.06 
AA/EPA NA NA NA NA NA NA 1.70±0.37* 1.60±0.22* 1.56±0.11* 0.18±0.01 0.18±0.02 0.20±0.03 NA 
              
16:1/16:0 0.04±0.00 0.08±0.01 0.12±0.00 0.06±0.01b 0.08±0.01a 0.11±0.00a 0.22±0.01 0.28±0.01 0.29±0.03 0.11±0.00 0.14±0.00 0.17±0.01 0.29±0.02 
18:1/18:0 1.01±0.07* 1.13±0.11* 1.32±0.18* 1.00±00.01* 1.11±0.20* 1.51±0.14* 2.59±0.06 3.91±0.30 4.99±0.30 2.13±0.02 0.±0.81 5.10±0.77 3.39±0.81 
18:1/16:0 0.12±0.02 0.15±0.02 0.20±0.05 0.09±0.00* 0.15±0.01* 0.20±0.02* 0.19±0.01 0.29±0.02 0.41±0.06 0.12±0.00 0.16±0.01 0.23±0.02 0.53±0.11 
Desaturation                   
index 
0.49±0.22* 0.43±0.03* 0.57±0.09* 0.25±0.01* 0.35±0.01* 0.44±0.04* 0.70±0.04*b 0.99±0.03* 1.23±0.11*a 0.34±0.00*c 0.45±0.02*b 0.62±0.03*a 1.30±0.22 
              
Delta 6 S 0.45±0.14 0.57±0.03 0.57±0.19 8.89±0.57*c 6.56±0.73*b 5.01±0.64*a 2.99±0.53*b 2.31±0.18*a 1.89±0.24*a 5.52±1.53*b 2.99±1.12*a 2.01±0.45a 0.61±0.30 
Delta 6 P 0.05±0.02*b 0.11±0.02a 0.19±0.10a 2.54±0.17*c 2.93±0.36*b 0.65±0.06*a 0.50±0.06* 0.51±0.05* 0.48±0.08* 0.09±0.0*c 0.11±0.01b 0.18±0.03a 0.15±0.07 
Delta 6 S/P 11.17±4.59*b 5.29±0.82a 3.68±0.62a 3.50±0.19b 2.25±0.44b 7.77±1.17*a 5.90±0.41b 4.56±0.14 3.99±0.17a 63.9±4.81*c 26.55±7.81b 11.57±2.85a 4.97±3.48 
              
              
PE FA ratios              
N6/N3 7.12±2.36*b 3.36±0.17a 3.29±0.82a 19.6±0.26*c 16.9±1.48*b 8.40±0.78*a 1.96±0.35 1.63±0.19 1.79±0.03 0.51±0.06* 0.63±0.26* 0.84±0.14* 2.22±1.01 
P/S 0.46±0.31* 0.53±0.03* 0.31±0.16* 2.84±0.29*b 2.82±0.30*b 1.64±0.10*a 0.85±0.11 0.80±0.03 0.96±0.12 2.89±0.16*b 1.99±0.35*a 1.93±0.28*a 1.01±0.30 
AA/EPA 23.4±6.7*b 17.9±2.06* 14.3±5.55a NA NA NA 1.90±0.55* 2.7±0.13* 3.2±0.16* 0.43±0.01* 0.40±0.01* 0.43±0.02* 10.78±2.5 
              
16:1/16:0 0.12±0.03* 0.19±0.03* 0.17±0.05* 0.11±0.02* 0.14±0.01* 0.18±0.02* 0.44±0.02b 0.47±0.01 0.62±0.14*a 0.17±0.02 0.28±0.01 0.28±0.01 0.40±0.09 
18:1/18:0 1.16±0.14* 1.15±0.05* 1.25±0.15* 0.62±0.01*b 0.84±0.11*a 0.98±0.05*a 1.80±0.08 1.98±0.02 1.98±0.15 0.80±0.04 1.34±0.06 1.34±0.06 1.98±0.35 
18:1/16:0 0.20±0.06* 0.28±0.01* 0.28±0.08* 0.36±0.10*b 0.56±0.05* 0.93±0.15a 0.54±0.05* 0.72±0.08* 0.91±0.14 0.60±0.13 0.71±0.12 0.71±0.12 1.08±0.29 
Desaturation 
index 
0.65±0.23* 0.88±0.02* 0.84±0.07* 0.54±0.07*b 0.79±0.04* 1.07±0.10*a 1.53±0.03 1.70±0.03 1.89±0.07 0.81±0.02 0.94±0.04 1.19±0.07 1.68±0.32 
              
Delta 6 S 0.42±0.39 0.17±0.01* 0.23±0.06* 6.31±0.35*c 3.87±0.98*b 2.32±0.65*a 1.65±0.23* 1.28±0.28* 1.18±0.28* 4.43±1.23*b 2.64±0.71*a 2.20±0.46*a 0.71±0.28 
Delta 6 P 0.14±0.6* 0.23±0.03* 0.21±0.08* 3.41±0.52*b 3.77±0.22*b 1.60±0.17*a 0.87±0.10 1.02±0.07 0.88±0.18 0.42±0.08 0.49±0.13 0.56±0.04 0.64±0.31 
Delta 6 S/P 2.60±1.61* 0.73±0.07 1.34±0.85 1.88±0.28 1.02±0.22 1.46±0.36 1.91±0.26 1.17±0.32 1.35±0.06 10.3±0.87*c 5.58±1.52*b 3.76±0.82*a 1.44±0.98 
AA PC/PE 0.25±0.04b 0.35±0.03b 0.57±0.27*a 0.76±0.13* 0.60±0.04* 0.66±0.10* 0.66±0.13* 0.50±0.07* 0.55±0.06* 0.35±0.01* 0.33±0.06* 0.31±0.15* 0.20±0.06 
              
Values are expressed as mean (µg fatty acid/mg protein) ± SD of 4 replications. * denotes significant (P<0.05) difference compared to control. The letters (a,b and c) denote a significant (P<0.05) difference between treatment according to ANOVA 
(analysis of variance) analyses, where a, b and c are all different. FA = fatty acid, mM = treatment concentration in mM, N6 PUFA = omega 6 polyunsaturated fatty acids, N3 PUFA = omega 3 polyunsaturated fatty acids, PUFA = polyunsaturated 
fatty acids, FA containing 2 or more double bonds, CLA = conjugated linoleic acid, C9T11 = cis9-trans11 CLA, T10C12 = trans10-cis12 CLA, N6/N3 = omega 6/omega 3 ratio, P/S = polyunsaturated./saturated fatty acid ratio, AA/EPA = 
arachidonic acid/eisocapentanoic acid ratio, C20:4n6/C20:5n3, Delta 6 S = substrate for Δ-6 desaturase, Delta 6 P = product of Δ-6 desaturase, Delta 6 S/P = ratio of Δ-6 desaturase substrate/product, NA = not available, EPA is undetected. 
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5.5. Discussion 
This study explores the effect of c9t11 CLA, t10c12 CLA, LA and ALA on fatty acid 
incorporation, phospholipids and cholesterol in the membranes of HepG2 cells. The cellular 
membrane consists of a phospholipid bilayer. Each phospholipid contains two FA chains and 
it is well documented that the types of FA they contain affect membrane fluidity, the transfer 
of nutrients across the membrane and intercellular communication (Spector and Yorek, 
1985). The FA composition of the cell membrane can easily be modified by dietary intake of 
fatty acids. 
For the purpose of this study, cells were exposed to FA conjugated to BSA in the culture 
medium. This clearly affected the FA profile of the cell membrane after 48 hour incubation. 
All supplemented FA incorporated well into the cell membrane of HepG2 cells. The 
treatment concentrations were based on the ATP IC50, BrdU IC50 results and a concentration 
positioned between the two IC50s as defined in Chapter 4 - Table 4.1, were chosen. The FAs 
were incorporated into the PC and PE membrane fractions in a dose dependent manner. Thus, 
as the treatment concentration increased, the amount of FA detected in the sample increased 
proportionally and vice versa. The fatty acids were however incorporated better into the PC 
fraction than the PE phospholipid fraction of the cell membrane. Based on supplementation 
concentration, LA and c9t11 CLA were the best incorporated fatty acids and t10c12 was the 
least best incorporated fatty acid. CLA isomers did not affect the phospholipid concentration 
of the PC fraction, which was reduced dose dependently in the PC phospholipid fraction of 
HepG2 cell membranes. Regarding the effect on membrane composition, the t10c12 CLA 
seems to have a lesser effect than c9t11 CLA in that the t10c12 CLA mostly has effect on 
MUFA while c9t11 CLA seems to affect all FA groups, i.e. SATS, MUFA, N6, N3 and this 
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pattern seems consistent for PC and PE. As expected, ALA increased N3 FA and LA 
increased the composition of N6 FA, which is consistent in both PC and PE. 
FA supplementation did not significantly affect the cholesterol content in the cell membranes 
of HepG2 cells. This finding was consistent with a previous study that looked at the effect of 
CLA isomers and LA on the distribution of cholesterol in lipid rafts and non-raft lipids 
(Subbaiah et al., 2011). 
CLA alters the desaturation index and Δ9-desaturase activity in HepG2 cells and t10c12 CLA 
has the greater effect than c9t11 CLA (Subbaiah et al., 2011). CLA reduces the expression 
and activity of Δ9 desaturase, the enzyme involved in converting SATS to MUFA by 
catalysing the formation of a cis-double bond at carbon-9 position of the SATS (Zhang et al., 
2010). The desaturation ratios that can be identified in the present study are 16:1n7/16:0, 
18:1n9/18:0 and 18:1n7/16:0. All desaturation ratios have been greatly reduced following FA 
supplementation by all FA. The most outspoken effect in the desaturation of SATS to MUFA 
was observed in samples treated with t10c12 CLA and LA. The t10c12 CLA also showed low 
Δ6 (desaturation of 18:2n6 to 18:3n6) and Δ5 (desaturation of 18:3n6 to 18:4n6) desaturase 
activity. These findings are consistent with previous studies indicative of the FA metabolism 
altering effect of t10c12 CLA, and increased prostaglandin formation (Eder et al., 2002).  
N6 FA cannot be converted to N3 FA in humans because of the absence of the Δ15-desaurase 
enzyme. Cancer cells are known to produce FA to maintain cell integrity through de novo 
synthesis (Berquin et al., 2011). The process involves the conversion of Acetyl-CoA leading 
to the formation of C18:1n9 and C20:4n3. This could explain the result of treatment with 
c9t11 CLA in Table 5.1 and 5.2. C18:1n9 is significantly higher than the control and the long 
chain N3 FA also increased significantly, indicating a possible response of de novo FA 
synthesis. 
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C20:4n6 (Arachidonic acid, AA) and C20:5n3 (Eicosapentaenoic acid, EPA) are important 
precursors of lipid mediator molecules involved in inflammation, proliferation, apoptosis and 
angiogenesis. These FA are substrates for a number of enzymes belonging to COX and LOX 
families in the production of prostaglandins, thromboxanes and leukotrienes (Berquin et al., 
2011). EPA and DHA are precursors for anti-inflammatory lipid mediators while AA is a 
precursor for pro-inflammatory lipid mediators (Azrad et al., 2013). The results show that 
c9t11 CLA increase AA, EPA and DHA in both PC and PE cellular membrane fractions, 
suggesting an antagonistic effect with regard to pro- and anti-inflammatory lipid mediators. 
The t10c12 CLA isomer showed insignificant suppression of AA, EPA and DHA, suggesting 
possible suppression in eicosanoid production, consistent with previous findings (Eder et al., 
2002, Eder et al., 2003). 
The results show that treatment with FA alters the lipid profile and FA metabolism of HepG2 
cells. It is clear that the two CLA isomers, c9t11 CLA and t10c12 CLA, produced different 
outcomes with regard to the proliferation altering mechanism of each isomer. The c9t11 CLA 
increased desaturation of PUFA and lowered the N6/N3 ratio, whereas t10c12 suppressed 
desaturation of SATS and increase the N6/N3 ratio. AA and EPA were increased by c9t11 
and suppressed by t10c12, suggesting altering effects on lipid mediator production. Indicating 
that the anti-carcinogenic mechanism of c9t11 CLA involves inflammation, apoptosis and 
cell proliferation, however the exact mechanism of t10c12CLA is yet to be established. 
Therefore further studies in cycle events and gene expression are required to fully uncover 
the anticancer effect of CLA. 
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6. General discussion and conclusion 
6.1. Introduction 
Cancer cells possess a number of characteristics that are vital to their immortality. These 
phenotypic characteristics contrast to what is considered normal characteristics of normal 
cells, i.e. altered pathways in growth signals, evasion of  apoptosis and protection from 
cellular stress signals (Santos and Schulze, 2012). Cellular stress signals resulting from 
changes in cancer cell metabolism or unfavourable tumour microenvironment, such as 
hypoxia and glucose deprivation, initiate the cellular stress response to ensure the cell’s 
survival (Kim et al., 2014). The cellular stress response includes: evasion of apoptosis, 
unfolded protein response and autophagy, which may contribute to carcinogenesis, tumour 
progression, and also treatment resistance, since most current anticancer treatments act by 
stimulating cell death pathways, like apoptosis in cancer cells. (Fulda, 2010). 
Fatty acids are essential building blocks of cell membrane and play an important role in 
cellular energy and signalling molecules. The fatty acid composition of cell membranes has a 
significant effect on many cellular processes. Research suggests that altering the fatty acid 
profile of cellular membranes may play a role in human health (Bondia-Pons et al., 2007). 
Modifications to the lipid profile of cellular membranes alter membrane fluidity as well as 
many cellular functions, including transport of extracellular molecules via carrier-mediated 
transport, prostaglandin production and cell growth (Spector and Yorek, 1985).  
The present study explored three different areas that could possibly affect the tumour 
development process. Firstly, the antioxidant activity of CLA isomers was studied. 
Antioxidants are chemicals that block the activity of free radicals and reactive oxygen 
species, which are highly reactive and have the potential to cause damage to cellular 
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components that may lead to cancer. Secondly, this study explored the cytotoxicity of CLA 
on HepG2 cells and addressed their effect on cell viability, apoptosis and cell proliferation. 
Finally, the effect of CLA on cell membrane fatty acid composition was evaluated and 
proposed possible effects that contribute to the anti-tumour properties of CLA. 
 
6.2. Antioxidant activity (Chapter 3) 
The antioxidant activity of c9t11 CLA and t10c12 CLA was evaluated by measuring the 
protection against iron-induced lipid peroxidation in rat liver microsomes by the TBARS 
method. When the microsomes were treated with varying concentrations of C18 FA’s, there 
was a clear difference in the level of iron-induced lipid peroxidation. Each fatty acid showed 
varying degrees of protection, but certain groupings were evident. Mono-unsaturated FA 
displayed the greatest protection, which can be attributed to the availability of a single 
hydrogen bond for free radical attack thereby producing fewer lipid peroxides. 
Polyunsaturated fatty acids were clustered together, with the highest and lowest effect at each 
concentration level spanning less than 20%.  
Each PUFA displayed a slight difference in effect as indicated by the different TBARs IC50 
levels depicting protection against lipid peroxidation. In order of most to least protection, LA 
has the lowest IC50, followed by c9t11, t10c12 and finally ALA with the highest IC50. This 
drove the conclusion, that the number and position of the double bond played an effectual 
role in the susceptibility to iron-induced lipid peroxidation. MUFA showed the highest 
protection and the lowest IC50, PUFAs with 2 double bonds (LA and CLA) were in the 
middle, while PUFAs with three double bonds showed least protection and therefore the 
highest IC50 concentration. Linoleic acid and the 2 CLA isomers each have 2 double bonds 
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and differ only in their position and arrangement. The same can be said with ALA and GLA, 
with 3 double bonds differing in their position. These two groups did not produce the same 
effect, but effectual differences could be seen possibly linked to the distance of the double 
bond closest to the methyl end of the fatty acid chain. Linoleic acid (C18:2n6) has its first 
double bond at carbon position 6 from the methyl end, c9t11 CLA at position 9 and t10c12 at 
position 10. Similarly, the effect can be seen with ALA (C18:3n3), with its first double bond 
methyl end at carbon position 3, and GLA (C18:3n6), which has its first double bond at 
carbon position 6 from the methyl end. This led to the summation that the positions of the 
double bond also play a role in iron-induced lipid peroxidation. 
Polyunsaturated fatty acids are highly susceptible to lipid peroxidation when exposed to free 
radicals. Free radicals attack the double bonds closest to the tail of the FA chain, thereby 
forming lipid peroxides. Lipid peroxidation plays an important role in cell membrane damage 
and increase in membrane permeability due to the presence of oxidized lipids (Wong-
Ekkabut et al., 2007). Not only are the cell membranes affected, intracellular oxidative stress 
as well as irreversible oxidative damage also occurs, ultimately leading to cell death (Repetto 
et al., 2012). In this study we saw that c9t11 and t10c12 CLA isomers did not significantly 
affect iron-induced lipid peroxidation differently compared to supplementation with LA or 
ALA. If the outcome was to reduce lipid peroxidation, supplementation with MUFA would 
be the best option, but in the scope of this study, this was not the main objective. The present 
study showed that introducing CLA isomers to the cell membranes did not significantly differ 
from what was observed when introducing LA or ALA. This indicates that if CLA was 
introduced via the diet for example, has a similar effect to LA with regard to lipid 
peroxidation and the protection thereof.  
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6.3. Growth parameters (Chapter 4) 
FAs possess multifaceted effects on the survival of cancer cells. They have been implicated 
in altering cancer cell proliferation and growth signals (Stephenson et al., 2013), and 
affecting apoptosis (Corsetto et al., 2011). In ideal situations, an effectual anticancer agent 
would be cytotoxic to only the cancerous cells and not healthy cells and tissue. The agent 
should decrease cell viability, increase apoptosis and retard the proliferation of these cells. 
The present study showed the effect of c9t11 CLA and t10c12 CLA on cytotoxicity, cell 
viability, apoptosis and cell proliferation in HepG2 cells was determined and compared to 
effects elicited by LA and ALA. The results have shown that each FA that was used affected 
each parameter differently, but the outcomes were generally the same. These results were 
increased cytotoxicity, decreased cell viability, increased apoptosis and a decreased cancer 
cell proliferation at different levels for each FA. Between the 2 CLA isomers, c9t11 CLA 
showed greater cytotoxicity than t10c12 CLA, which is also reflected in cell viability. c9t11 
CLA reduced cell viability to a greater extent than t10c12 CLA. All supplemented FAs 
reduced cell proliferation, however slight differences were evident with least effect observed 
with LA where no IC50 could be calculated. The c9t11 CLA and ALA effect was the greatest 
and almost overlapped (Chapter 4; Figure 4.3). With regards to apoptosis, caspases are 
effector molecules in all the apoptotic pathways leading to DNA fragmentation, membrane 
blebbing and formation of apoptotic bodies (Tawa et al., 2004). Here again c9t11 CLA 
showed a much greater effect on apoptosis fold increase than the t10c12 CLA isomer. These 
findings suggest that different mechanisms of action exist between c9t11 and t10c12 CLA in 
reducing cancer cell growth parameters.  
With regard to cytotoxicity, cell viability and cell proliferation, the effect between the 2 CLA 
isomers were not the same but showed similar trends. However, the effect on apoptosis was 
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substantially different. This could mean that t10c12 CLA may possess anticancer properties 
that to a lesser extent involve apoptosis and more actively involve effects on cell growth 
involving cell cycle arrest and senescence.  Of interest is that, t10c12 CLA was shown to be a 
greater inhibitor of the genes regulating cell cycle and growth than c9t11 CLA (Kelley et al., 
2007).  
 
6.4. Lipid profile (Chapter 5) 
Fatty acids play a major role in the structure and function of cellular membranes. Certain FAs 
are important for maintaining membrane structure and integrity and are involved in signalling 
and regulating the cell’s response to its environment. Modifications to the lipid profile of the 
cell membrane have been shown to alter a number of cellular processes such as cell 
proliferation and prostaglandin production (Berquin et al., 2011).  
HepG2 cells were supplemented with c9t11 CLA, t10c12 CLA, LA and ALA to determine 
effects on the membrane lipid profile. A distinct change in the FA composition of the cellular 
membrane was observed compared to unsupplemented control samples. In general, LA 
increased omega 6 (N6) fatty acids and ALA increased omega 3 (N3) FA, as predicted.  
Supplementation with t10c12 CLA reduced the MUFA of both PC and PE fractions of the 
cell membrane. LA, ALA and t10c12 CLA also decreased the desaturation index in both PC 
and PE phospholipid fractions. This finding suggests that these FA may moderate the activity 
of Δ9-desaturase, which is the enzyme involved in converting SATS to MUFA. Tumour cells 
obtain most fatty acids, to maintain high levels of proliferation, by de novo synthesis. 
Therefore, increased expressions of biosynthetic enzymes that are required to produce the 
large amounts of FA that are essential for maintaining the cancer phenotype 
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(Mohammadzadeh et al., 2014). The Δ9-desaturase enzyme is an important regulatory 
enzyme in cellular de novo fatty acid synthesis and has been implicated in the proliferation of 
cancer cells (Luyimbazi et al., 2010). 
When looking at the outcome of this study (Chapter 5), it is evident that supplementation 
with c9t11 CLA significantly increased C20:4n6 (Arachidonic acid, AA) and C20:5n3 
(Eicosapentaenoic acid, EPA) in both PC and PE phospholipid fractions of the cell 
membrane. AA and EPA are important precursors of lipid mediator molecules involved in 
inflammation, proliferation, apoptosis and angiogenesis. EPA is a precursors for anti-
inflammatory lipid mediators while AA is a precursor for pro-inflammatory lipid mediators 
(Azrad et al., 2013). 
 
6.5. Conclusion 
Cell proliferation, death and senescence control in normal mammalian cells and cancer cells 
are related to the regulation of metabolism, in particular the synthesis and remodelling of 
lipid modulators and structures (Igal, 2010). Elevated rate of aerobic glycolysis and an 
accelerated biosynthesis of macromolecules, including DNA, proteins and lipids, are 
characteristic in the metabolism in cancer cells (DeBerardinis et al., 2008). An essential 
aspect of the remodelled metabolism of transformed cancer cells is an increased rate of lipid 
biosynthesis (Baenke et al., 2013). Lipid metabolism modifications can influence many 
cellular processes, including cell growth, proliferation, differentiation and motility (Santos 
and Schulze, 2012). 
It is shown in the present study that c9t11 and t10c12 CLA are incorporated into the cell 
membrane of HepG2 cells. Their incorporation has a consequential inhibiting effect on cell 
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proliferation of cancer cells that may be associated with the altered lipid profile of the cellular 
membrane.  
The c9t11 CLA isomer markedly increased apoptosis and the overall FA content of the 
cellular membrane. This increased a number of factors that contribute to the effect of 
programmed death seen on cancer cells. These include increased MUFA concentrations, 
which reduces overall susceptibility to lipid peroxidation, thereby preventing cellular stress 
and allowing the cells to follow their normal cycle towards cell death. Moreover, increasing 
the total FA content of the cell membrane suggest increase de novo synthesis of FA, that are 
required for the formation of new cells, but could also be implicated in the formation of 
apoptotic bodies, which are membranous bodies containing cell fragments that are formed at 
the end of the apoptosis process. 
The t10c12 CLA isomer reduced cell proliferation comparable to c9t11 CLA (Chapter 4; 
Table 4.1); however c9t11 was more effective in increasing apoptosis and decreasing cell 
viability, similar to ALA. This suggests that the cell proliferation reducing effect of t10c12 
CLA may be the result of a different mechanism. The t10c12 CLA isomer showed to reduce 
delta-9 desaturase activity, which is an essential enzyme in de novo synthesis of FA, 
indicated by reduction in MUFA composition of the cell membrane of HepG2 cells. Limiting 
de novo FA synthesis effectively reduces the FA availability required for proliferation of new 
cells. This could explain the effect seen in the cell proliferation assay. EPAs are precursors to 
anti-inflammatory modulatory molecules that have been implicated in prostaglandin 
production, which could suggest another mechanism of action of CLA.  
When looking at Table 4.1 in Chapter 4, c9t11 seems to mimic the effectiveness of ALA on 
of viability, cell proliferation and apoptosis in HepG2 cells. c9t11 also increased N6 and N3 
PUFA, potentially increasing cell susceptibility to decreased survival and growth despite the 
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increased SATS and MUFA.  The antioxidative potential of c9t11 CLA was greater than 
t10c12 CLA; this in addition to c9t11’s greater effectiveness on cell viability and apoptosis, 
and the difference between the 2 CLA isomers could make c9t11 a more effective anticancer 
agent. 
The evidence exists in literature that reduction of cell proliferation exhibited by CLA may be 
attributed to the aggregation of cells in the S phase of the cell cycle and apoptosis via 
mechanisms involving the mitochondrial pathway (Miglietta et al., 2006). CLA also elicited 
cell cycle arrest in G1 phase and induced tumour suppressor protein accumulation (Kemp et 
al., 2003). Isomer specifically, t10c12 indicated that t10c12-induced p21 (CIP1/WAF1) binds 
to cyclin dependent kinases (CDK), thereby inhibiting the enzyme activity, which contributed 
to the decrease in the G1-S progression potentially. (Kim et al., 2006). There are yet to be 
fully explained; therefore further studies in cycle events and gene expression are required to 
fully uncover the anticancer mechanisms of both c9t11 and t10c12 CLA isomers. 
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BCA (Pierce) Protein Determination Assay 
 
Solutions required 
 2% SDS Solution 
 BCA Protein Reagent A 
 BCA Protein Reagent B (4% CuSO4.5H2O) 
 BSA Standard (1mg/ml) 
 Distilled H2O 
2% SDS Solution Reagent A Reagent B BSA 
Make your own Purchase from 
Seperations 
Make your own  
2Mm EDTA  4% CuSO4.5H2O  
20Mm NaHCO3    
2% Sodium dodecyl 
sulphate 
   
Working Reagent preparation 
Mix Solution A and Solution B in a 50:1 ratio 
Standard preparation 
 BSA(µl) 2% SDS(µl) Working Reagent(µl) 
Blank 0 100 200 
S1 5 95 200 
S2 10 90 200 
S3 20 80 200 
S4 30 70 200 
S5 40 60 200 
S6 50 50 200 
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Unknown samples 
Sample(µl) 2% SDS(µl) Working Reagent(µl) 
25 75 200 
*Smaller volume of sample can be used – just ensure that sample and SDS does not exceed 
100μl. 
Procedure 
1. Pipette each standard and sample into a microplate well.  
2. Add the working reagent. 
3. Cover plate and incubate at 37°C for 30 minutes. 
4. Cool plate to room temperature. 
5. Measure the absorbance at 562nm on plate reader. 
Standard curve 
 
Equation:  y = mx + c 
y = Absorbance reading (nm) 
m = slope 
x = protein concentration (mg/ml) 
c = y-intercept 
y = 63.444x + 0.0314 
R² = 0.9823 
0.000
0.100
0.200
0.300
0.400
0.500
0.600
0.700
0 0.002 0.004 0.006 0.008 0.01 0.012
a
b
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protein in mg/ml 
BSA standard curve 
Series1
Linear (Series1)
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Esterbauer and Cheeseman (1990), Methods Enzymol. 186: 407-421 
Yen & Hsieh, (1998), J. Agric. Food Chem. 46: 3952-3957 
Hu et al., J. Nutr. (1989), 119: 1574-1582 
ASSESSMENT OF LIPID PEROXIDATION: 
MDA (Malondialdehyde) or TBARS ASSAY 
REAGENTS: 
- TCA Reagent (10 % TCA, BHT [see below] & 1mM EDTA) – Make up fresh 
- 0.67% TBA solution in distilled water – Make up fresh:Weigh out amount of TBA 
powder needed and mix with less than needed amount of water, heat at approx. 45°C-
50°C until dissolved, cool to room temp. Then make up to desired volume in a 
volumetric flask. 
- 1.15% KCl containing 0.01 M potassium phosphate buffer (pH 7.4) 
- FeSO4 solution (2.5mM ferrous sulphate; 69.5mg/100ml dist. water) – Make up fresh 
- BHT (stock = 8g/100ml ethanol, kept in walk in fridge), add 0.125ml/100ml TCA-
EDTA (BHT does not dissolve easily in an aqueous solution, will flocculate) 
NB:  For all steps work on ice 
Only make up the required amount of reagents (TCA, TBA, as required per assay) 
Homogenate preparation 
 Homogenise tissue samples on ice in 19 volumes of 1.15% KCl in phosphate buffer using 
glass hand Dounce (dounce approx. 10 x) and store at -80°C. 
 Microsomes (stored at -80°C) for determination of anti-oxidative activity should be 
dounced on ice before use (10x, loose dounce) 
 Determine protein concentration  
(NB:  Dilute samples for protein assay with 2% SDS solution approx. 50-60x, microsomes 
50x). 
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METHOD 
- Use 1mg protein per unknown sample/microsomes 
Note: Use 1mg protein per test tube, therefore 0.5ml sample must contain 2mg protein.  This 
will equate to 1mg protein per 1ml total test tube reaction volume. 
- Run 2x blanks through the procedure containing sample buffer only (1.15% KCl in 
phosphate buffer) 
- Dilution of tea samples may need to be pre-determined, a range of dilutions should be 
used to determine the IC50 value 
 Treatment with iron (Table 1) 
- Vortex and incubate at 37°C for 1 hr in a shaking waterbath. 
- Thereafter, place tubes on ice and follow the assay procedure. 
Table 1 pipetting scheme for testing antioxidant potential of  tea/oil etc.  samples using 
microsomes 
 Antioxidant KCl-
buffer 
FeSO4 Microsomes 
(2mg/ml) 
Total 
volume 
Reagent blank --------- 0.8ml 0.2ml --------- 1ml 
Microsomes 
blank 
--------- 0.5ml --------- 0.5ml  1ml 
Positive control --------- 0.3ml 0.2ml 0.5ml 1ml 
Samples  
(teas, oils, etc.) 
 
0.1ml 
 
0.2ml 
 
0.2ml 
 
0.5ml  
 
1ml 
 
Table 2 pipetting scheme for determination of TBARS in tissue homogenates 
 protein KCl-buffer FeSO4 Homogenate  Total 
volume 
Reagent blank --------- 0.8ml 0.2ml --------- 1ml 
Samples as is 
(liver 
homogenates) 
 
±10mg/ml 
 
0.7ml 
 
0.2ml 
 
0.1ml  
 
1ml 
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Assay procedure: 
- add 2ml TCA reagent (10% TCA with BHT & EDTA) to each tube (Addition of 
EDTA and BHT to the TCA reagent prevents further oxidative damage during the 
assay procedure) 
- Vortex and centrifuged at 2000 rpm for 15 min. 
- Take off 2ml of the supernatant, add to a new test tube and add 2 ml 0.67% TBA 
solution 
- Vortex and heat in capped tubes at 90ºC for 20 min in a water-bath. 
- Allow mixture to cool (ice bath) 
- Measure absorbency at 532 nm on spectrophotometer, use distilled water as blank and 
read sample blanks as well as unknown samples.  Use glass 2ml or 4ml cuvettes.  
Plastic cuvettes get bubbles forming. 
 
Lipid peroxidation is expressed as nmol MDA equivalents per mg protein, using the molar 
extinction coefficient of 1.56 x 10
5
 M
-1
 cm
-1
 at 532 nm for MDA or the standard curve 
(Esterbauer and Cheeseman, 1990).Esterbauer and Cheeseman (1990), Methods Enzymol. 
186: 407-421 
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Product  size Cat.# 
CellTiter-Glo®Luminescent Cell Viability Assay 10 ml G7570 
Substrate is sufficient for 100 assays at 100μl/assay in 96-well plates or 400 assays at 
25μl/assay in 384-well plates. Includes: 
• 1 × 10ml CellTiter-Glo® Buffer 
• 1 vial CellTiter-Glo® Substrate (lyophilized) 
Mix together before use. 
 
Protocol:  
1. Prepare opaque-walled multiwell plates with mammalian cells in culture medium 100μl 
per well for 96-well plates.  
2. Prepare control wells containing medium without cells to obtain a value for background 
luminescence. 
3. Add the test compound to experimental wells, and incubate according to culture protocol. 
4. Equilibrate the plate and its contents at room temperature for approximately 30 minutes. 
5. Add a volume of CellTiter-Glo® Reagent equal to the volume of cell culture medium 
present in each well (e.g., add 100μl of reagent to 100μl of medium containing cells for a 96-
well plate, or add 25μl of reagent to 25μl of medium containing cells for a 384-well plate). 
6. Mix contents for 2 minutes on an orbital shaker to induce cell lysis. 
7. Allow the plate to incubate at room temperature for 10 minutes to stabilize luminescent 
signal. 
8. Record luminescence. 
Note: Instrument settings depend on the manufacturer. An integration time of 0.25–1 second 
per well should serve as a guideline. 
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Product  size Cat.# 
Caspase-Glo®3/7 Assay  100ml ZZG8092 
Each system contains sufficient reagents for 1,000 assays at 100μl per assay in a 96-well 
plate or 4,000 assays of 25μl per assay in a 384-well plate. Includes: 
• 1 × 100ml Caspase-Glo® 3/7 Buffer 
• 1 bottle Caspase-Glo® 3/7 Substrate (lyophilized) 
Mix together before use. 
 
Standard Protocol for Cells Cultured in a 96-Well Plate 
1. Before starting the assay, prepare the Caspase-Glo®3/7 Reagent. Allow the reagent to 
equilibrate to room temperature. Mix well. 
2. Remove 96-well plates containing cells from the incubator and allow plates to equilibrate 
to room temperature. 
3. Add 100μl of Caspase-Glo®3/7 Reagent to each well of a white-walled 96-well plate 
containing 100μl of blank, negative control cells or treated cells in culture medium.  
4. Gently mix contents of wells using a plate shaker at 300–500rpm for 30 seconds. Incubate 
at room temperature for 30 minutes to 3 hours, depending upon the cell culture system.  
5. Measure the luminescence of each sample in a plate-reading Luminometer as directed by 
the luminometer manufacturer. 
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CHOLESTEROL DETERMINATION 
Adapted from  – Richmond (1973). Clin. Chem., 19: 1350-1356. 
   – Smuts et al. (1994). Cor. Art. Dis. 5: 331-338 
 
Reagents: 
(1) Cholesterol Colour Reagent: 
To one liter volumetric flask add the following: 
KH2PO4        22,1827 g 
K2HPO4.3H2O                  8,4445 g 
KI         19,9212 g 
NaN3         9,7515 g 
Alkylbenzyldimethylammonium chloride     100 mg 
Ammonium molbydate      12,4 mg 
Triton X-100 (polyethylene glycol monether; peroxide free)2 g 
 
(2) Cholesterol Reagent B: 
Cholesterol esterase  83.3 l 
Cholesterol oxidase   125 l 
3M NaCl    1792 l 
 
Method: 
(1) Use 20 µl of the lipid sample from CMS extraction used for TLC spotting. 
(2) Add 50 µl CM, vortex. 
(3) Add 300 µl 1% Tritin-X100 (peroxide free), vortex. 
(4) Evaporate emulsion under N2, vortex until clear. 
(5) Add 1.7 ml cholesterol reagent. 
(6) Standards: - 10 µl from 4 different cholesterol standard concentrations 
- 300 µl 1% Triton-X100 
- Add 1.7 ml cholesterol reagent 
      (7) Carry 1 ml over from (5) and (6) into small sample tubes and add 20 µl   
cholesterol Reagent B. 
(8) Add 20 µl 3 M NaCl to original tubes from (5) and (6). 
(9) Incubate at room temperature. 
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(10) Read at 365 nm with both VIS and UV bulbs on. Read each sample  
       together with its respective blank. 
 
Cholesterol content calculation: 
Colon polyps/mucosa 
 
                               fstandard  x faliquot x (
100
/CLW) x absorbancesample 
Ccholesterol  =            
         mcolon_protein [mg] 
 
 
RBC membranes 
                                fstandard x faliquot x absorbancesample 
Ccholesterol  =            
         Cprotein  
 
fstandard   average of n values: mstandard [µg]/ absorbancestandard 
faliquot   Vtotal CMS of sample [µl]/ Valiquot of CMS extract spotted for TLC [µl] 
CLW   colon lipid weight (mg) 
mcolon_protein [mg] mg sample protein per 100 mg colon protein dry weight 
Cprotein  RBC protein concentration (mg per ml) 
unit:   µg cholesterol per mg protein 
 
 
 
 
 
This letter serves to inform the reader that necessary corrections have been made to the MSc 
thesis titled: The Modulating Effect of Conjugated Linoleic Acid CLA on Cancer Cell 
Survival in vitro.  
 
Lyle Arendse           
15 February 2015 
 
 
 
 
